

Evaluation of TB diagnostic test accuracy using Bayesian latent class analysis in the presence of conditional dependence between the diagnostic tests used in a community-based TB screening study

3 Supplementary material

4 1. Model

Let the random variable $Y_j, j = 1, 2, \dots, J$ denote the j^{th} diagnostic test and the random variable D denote the latent disease status such that $Y_j = 0(1)$ if the j^{th} diagnostic test result is negative (positive) and $D = 0(1)$ if the true disease status is negative (positive). Under the assumption of conditional independence, the joint probability of a combination of test results from a set of J diagnostic tests $\mathbf{Y} = (Y_1, Y_2, \dots, Y_J)$ is given by [1]

10 However, for J dependent diagnostic tests, $Pr(Y)$ can be expressed using the chain rule of conditional probability
11 as follows

13 where

$$p_{dj} = Pr\left(Y_j = 1 \mid D = d \cap \bigcap_{j'=1, j' > 1}^{j-1} Y_{j'} = y_{j'}\right) \text{ and } \theta_d = Pr(D = d), d \in \{0,1\}$$

16 The probabilities p_{dj} and $\theta_d = \Pr(D = d), d \in \{0,1\}$ can be calculated using regression methods.

17 Consequently,

$$Pr(Y_j = 1 | D = d) = \sum_{Y_{j-1} \in (0,1)} \dots \sum_{Y_2 \in (0,1)} \sum_{Y_1 \in (0,1)} \prod_{k=1}^j p_{dk} \dots \dots \dots \dots \dots \dots \dots \quad (3)$$

19 and $Pr(Y_j = 0|D = d) = 1 - Pr(Y_j = 1|D = d)$.

20 The model can be extended to include covariates known to affect the diagnostic accuracy and/or prevalence such
21 that for a binary variable X , $Pr(\mathbf{Y})$ can be re-expressed as

$$22 \quad Pr(\mathbf{Y}) = \sum_{d=0}^1 \sum_{x=0}^1 Pr(X = x) Pr(D = d|X = x) \prod_{j=1}^J Pr\left(Y_j = y_j | X = x \bigcap D = d \bigcap_{j'=1|j>1}^{j-1} Y_{j'} = y_{j'}\right)$$

23 For a vector \mathbf{X} of p covariates, $Pr(\mathbf{X}) = Pr(X_1, X_2, \dots, X_p) = Pr(X_1)Pr(X_2|X_1) \dots Pr(X_p|X_1, X_2, \dots, X_{p-1})$.

24 1.1. Bayesian Inference

25 Since the likelihood function of $\mathbf{y}_i = (y_{i1}, y_{i2}, \dots, y_{ij})$ depends on the (latent) disease status d_i , $i = 1, 2, 3, \dots, N$, we
26 have

$$39 \quad Pr(\mathbf{y}_i, d_i | \theta, p_{d_{ij}}) = \left(\theta \prod_{j=1}^J p_{d_{ij}}^{y_{ij}} (1 - p_{d_{ij}})^{1-y_{ij}} \right)^{d_i} \left((1 - \theta) \prod_{j=1}^J p_{d_{ij}}^{y_{ij}} (1 - p_{d_{ij}})^{1-y_{ij}} \right)^{1-d_i} \dots \dots \dots (4)$$

27 We will only focus on the case where we have data on J diagnostic tests. Extension to incorporate covariates is
28 straight forward. From (4) we have J conditional probability models to fit to determine $p_{d_{ij}}, j = 1, 2, \dots, J$. Since the
29 outcome is Bernoulli distributed and $p_{d_{ij}}$ is related to a set of (binary) independent variables we can define a binary
30 regression model as $p_{id_{ij}} = H(\mathbf{y}_i^T \boldsymbol{\beta}_{dj})$, where $\mathbf{y}_i^T = (y_{i0}, y_{i1}, \dots, y_{ij})$ is a $(j + 1) \times 1$ vector of observed variables
31 (or diagnostic tests) with $y_{i0} = 1$, $\boldsymbol{\beta}_{dj}$ is a $(j + 1) \times 1$ vector of unknown parameters to be estimated, and $H(\cdot)$ is
32 a known cumulative distribution function (CDF) linking the probabilities $p_{id_{ij}}$ with the linear component $\mathbf{y}_i^T \boldsymbol{\beta}_{dj}$ [2].

33 The unknown parameters $\boldsymbol{\beta}_{dj}$ were assigned $g(\boldsymbol{\beta}_{dj}) = N(\boldsymbol{\mu}_{dj}, \boldsymbol{\sigma}_{dj}^2 I_{j+1})$ priors, where I_{j+1} is an identity matrix of
34 dimension $(j + 1)$ and $\boldsymbol{\sigma}_{dj}^2$ is a $(j + 1) \times 1$ vector of variances among subjects whose true PTB status is d . The
35 variances may not necessarily be the same (Tables S1 – S5). Similarly, the unobserved PTB status is a Bernoulli
36 distributed latent variable. Therefore, the probability θ_i that the i^{th} subject has PTB is related to a constant or a (set
37 of) covariate(s) as follows: $\theta_i = H(\mathbf{x}_i^T \boldsymbol{\omega})$, where $\mathbf{x}_i^T = (x_{i0}, x_{i1}, \dots, x_{ip})$ is a $(p + 1) \times 1$ vector of observed
38 covariates ($x_{i0} = 1$), $\boldsymbol{\omega}$ is a $(p + 1) \times 1$ vector of unknown parameters to be estimated, and $H(\cdot)$ is a known CDF

40 linking the probabilities θ_i with the linear component $x_i^T \boldsymbol{\omega}$. The unknown parameter(s) $\boldsymbol{\omega}$ were assigned $g(\boldsymbol{\omega}) =$
 41 $N(\boldsymbol{\mu}_{\boldsymbol{\theta}}, \boldsymbol{\sigma}_{\boldsymbol{\theta}}^2 I_{p+1})$ priors, where I_{p+1} is an identity matrix of dimension $p + 1$ and $\boldsymbol{\sigma}_{\boldsymbol{\theta}}^2$ is a $(p + 1) \times 1$ vector of variances
 42 (for now we are working with $p + 1 = 1$). Thus, the posterior distribution $g(\boldsymbol{\omega}, \boldsymbol{\beta}_{dj} | \mathbf{y}_i, d)$ is proportional to

$$43 g(\boldsymbol{\omega}) \prod_{i=1}^N \left(H(x_i^T \boldsymbol{\omega})^{d_i} (1 - H(x_i^T \boldsymbol{\omega}))^{1-d_i} \right) \times \left(\prod_{j=1}^J g(\boldsymbol{\beta}_{1j}) \prod_{i=1}^N \left(H(y_i^T \boldsymbol{\beta}_{1j}) \right)^{y_{ij} d_i} (1 - H(y_i^T \boldsymbol{\beta}_{1j}))^{(1-y_{ij}) d_i} \right)$$

$$44 \times \left(\prod_{j=1}^J g(\boldsymbol{\beta}_{0j}) \prod_{i=1}^N \left(H(y_i^T \boldsymbol{\beta}_{0j}) \right)^{y_{ij}(1-d_i)} (1 - H(y_i^T \boldsymbol{\beta}_{0j}))^{(1-y_{ij})(1-d_i)} \right) \dots \dots \dots \quad (5)$$

45 where $\int g(\boldsymbol{\beta}_{dj}) \prod_{i=1}^N \left(H(y_i^T \boldsymbol{\beta}_{dj}) \right)^{y_{ij}} (1 - H(y_i^T \boldsymbol{\beta}_{dj}))^{1-y_{ij}} d\boldsymbol{\beta}_{dj}$, $d \in \{0,1\}$ and $\int g(\boldsymbol{\omega}) \prod_{i=1}^N \left(H(x_i^T \boldsymbol{\omega}) \right)^{y_{ij}} (1 - H(x_i^T \boldsymbol{\omega}))^{1-y_{ij}} d\boldsymbol{\omega}$ are not easy to determine analytically. Thus, the unknown parameters $\boldsymbol{\omega}$, and $\boldsymbol{\beta}_{dj}$, $j = 1, 2, 3, \dots, J$
 46 will be estimated using Markov Chain Monte Carlo (MCMC) approach.

48 2. Prior distributions

49 Table S1 presents the models and the prior distributions for the parameters in the probit regression models for the
 50 analysis of CPTB study. Similarly, Tables S4 – S5 present the models and the prior distributions for the parameters in
 51 the probit regression models for the analysis of Vukuzazi study. The assumptions made on the potential
 52 dependencies for all the models were presented in the analysis section of the main document.

53 2.1. CPTB Data

54 In the analysis of CPTB data, we allowed TST (Y_1), radiography (Y_2), microscopy (Y_3), Xpert (Y_4) and culture (Y_5) as
 55 the possible ordering of the diagnostic tests.

56 Table S1: Prior distributions for the parameters in the probit regression models for childhood pulmonary TB data

Response	Model structure	Model 0	Model 1	Model 2	Model 3	Model 4
D	$Pr(D = 1) = \emptyset(\omega)$	$g(\omega) \sim N(0,1)$				
Y_1	$Pr(Y_{i1} = 1 D_i = 1) = \emptyset(\beta_{11})$	$g(\beta_{11}) \sim N(0,10)$				
	$Pr(Y_{i1} = 1 D_i = 0) = \emptyset(\alpha_{11})$	$g(\alpha_{11}) \sim N(0,10)$				
Y_2	$Pr(Y_{i2} = 1 Y_{i1}, D_i=1) = \emptyset(\beta_{12} + \beta_{22}y_{i1})$	$g(\beta_{12}) \sim N(0,10)$				
	$Pr(Y_{i2} = 1 Y_{i1}, D_i=0) = \emptyset(\alpha_{12} + \alpha_{22}y_{i1})$	$g(\alpha_{12}) \sim N(0,10)$				
Y_3	$Pr(Y_{i3} = 1 Y_{i1}, Y_{i2}, D_i=1)$ $= \emptyset(\beta_{13} + \beta_{23}y_{i1} + \beta_{33}y_{i2})$	$g(\beta_{13}) \sim N(0,10)$				
	$Pr(Y_{i3} = 1 D_i=0) = \emptyset(\alpha_{13})$	$g(\alpha_{13}) \sim N(-3, 0.1)$				
Y_4	$Pr(Y_{i4} = 1 Y_{i1}, Y_{i2}, Y_{i3}, D_i=1)$ $= \emptyset(\beta_{14} + \beta_{24}y_{i1} + \beta_{34}y_{i2} + \beta_{44}y_{i3})$	$g(\beta_{14}) \sim N(0,10)$				
	$Pr(Y_{i4} = 1 D_i=0) = \emptyset(\alpha_{14})$	$g(\alpha_{14}) \sim N(-3, 0.1)$				
Y_5	$Pr(Y_{i5} = 1 Y_{i1}, Y_{i2}, Y_{i3}, Y_{i4}, D_i=1)$ $= \emptyset(\beta_{15} + \beta_{25}y_{i1} + \beta_{35}y_{i2} + \beta_{45}y_{i3} + \beta_{55}y_{i4})$	$g(\beta_{15}) \sim N(0,10)$				
	$Pr(Y_{i5} = 1 D_i=0) = \emptyset(\alpha_{15})$	$g(\alpha_{15}) \sim N(-3, 0.1)$				

57 D – Disease (CPTB), Y_1 – TST, Y_2 – Radiography, Y_3 – Smear microscopy, Y_4 – Xpert MTB/RIF, Y_5 – Culture, “–” implies the parameter is not included (i.e set to
58 zero) in the model, Model 0 was based on the assumption of conditional independence, Model 1 was based on expert opinion [3], Model 2 adds dependency
59 between TST and radiography in non-CPTB cases to Model 1, Model 3 additionally allows dependency of all diagnostic tests with radiography among the true
60 CPTB cases. Model 4 is the reduced version of Model 3 that omits the dependence between TST and radiography in non-CPTB cases

61
62

Table S2: Prior distributions for the parameters in the probit regression models for Vukuzazi data

	Model structure	Model 0	Model 1	Model 2
D	$Pr(D = 1) = \emptyset(\omega)$	$g(\omega) \sim N(-3, 0.1)$	$g(\omega) \sim N(-3, 0.1)$	$g(\omega) \sim N(-3, 0.1)$
Y_1	$Pr(Y_{i1} = 1 D_i = 1) = \emptyset(\beta_{11})$	$g(\beta_{11}) \sim N(0, 0.1)$	$g(\beta_{11}) \sim N(0, 0.1)$	$g(\beta_{11}) \sim N(0, 0.1)$
	$Pr(Y_{i1} = 1 D_i = 0) = \emptyset(\alpha_{11})$	$g(\alpha_{11}) \sim N(0, 10)$	$g(\alpha_{11}) \sim N(0, 10)$	$g(\alpha_{11}) \sim N(0, 10)$
Y_2	$Pr(Y_{i2} = 1 D_i = 1) = \emptyset(\beta_{12})$	$g(\beta_{12}) \sim N(0, 0.1)$	$g(\beta_{12}) \sim N(0, 0.1)$	$g(\beta_{12}) \sim N(0, 0.1)$
	$Pr(Y_{i2} = 1 Y_{i1}, D_i = 0) = \emptyset(\alpha_{12} + \alpha_{22}y_{i1})$	$g(\alpha_{12}) \sim N(0, 10)$ -	$g(\alpha_{12}) \sim N(0, 10)$ -	$g(\alpha_{12}) \sim N(0, 10)$ $g(\alpha_{22}) \sim N(0, 10)$
Y_3	$Pr(Y_{i3} = 1 Y_{i2}, D_i = 1) = \emptyset(\beta_{13} + \beta_{23}y_{i2})$	$g(\beta_{13}) \sim N(0, 0.1)$ -	$g(\beta_{13}) \sim N(0, 0.1)$ $g(\beta_{23}) \sim N(0, 0.1)$	$g(\beta_{13}) \sim N(0, 0.1)$ $g(\beta_{23}) \sim N(0, 0.1)$
	$Pr(Y_{i3} = 1 Y_{i1}, Y_{i2}, D_i = 0) = \emptyset(\alpha_{13} + \alpha_{23}y_{i1} + \alpha_{33}y_{i2})$	$g(\alpha_{13}) \sim N(0, 10)$	$g(\alpha_{13}) \sim N(0, 10)$ -	$g(\alpha_{13}) \sim N(0, 10)$ $g(\alpha_{23}) \sim N(0, 10)$ $g(\alpha_{33}) \sim N(0, 10)$
Y_4	$Pr(Y_{i4} = 1 Y_{i2}, Y_{i3}, D_i = 1) = \emptyset(\beta_{14} + \beta_{24}y_{i2} + \beta_{34}y_{i3})$	$g(\beta_{14}) \sim N(0, 0.1)$ -	$g(\beta_{14}) \sim N(0, 0.1)$ $g(\beta_{24}) \sim N(0, 0.1)$ $g(\beta_{34}) \sim N(0, 0.1)$	$g(\beta_{14}) \sim N(0, 0.1)$ $g(\beta_{24}) \sim N(0, 0.1)$ $g(\beta_{34}) \sim N(0, 0.1)$
	$Pr(Y_{i4} = 1 Y_{i1}, Y_{i2}, Y_{i3}, D_i = 0) = \emptyset\left(\alpha_{14} + \alpha_{24}y_{i1} + \frac{\alpha_{34}y_{i2} + \alpha_{44}y_{i3}}{\alpha_{34}y_{i2} + \alpha_{44}y_{i3}}\right)$	$g(\alpha_{14}) \sim N(0, 10)$ -	$g(\alpha_{14}) \sim N(0, 10)$ -	$g(\alpha_{14}) \sim N(0, 10)$ $g(\alpha_{24}) \sim N(0, 10)$ $g(\alpha_{34}) \sim N(0, 10)$ $g(\alpha_{44}) \sim N(0, 10)$
Y_5	$Pr(Y_{i5} = 1 D_i = 1) = \emptyset(\beta_{15})$	$g(\beta_{15}) \sim N(0, 0.1)$	$g(\beta_{15}) \sim N(0, 0.1)$	$g(\beta_{15}) \sim N(0, 0.1)$
	$Pr(Y_{i5} = 1 D_i = 0) = \emptyset(\alpha_{15})$	$g(\alpha_{15}) \sim N(-1.88, 0.01)$ -	$g(\alpha_{15}) \sim N(-1.88, 0.01)$ -	$g(\alpha_{15}) \sim N(-1.88, 0.01)$ -
Y_6	$Pr(Y_{i6} = 1 D_i = 1) = \emptyset(\beta_{16} + \beta_{26}y_{i5})$	$g(\beta_{16}) \sim N(0, 0.1)$ -	$g(\beta_{16}) \sim N(0.84, 0.1)$ $g(\beta_{26}) \sim N(0, 0.1)$	$g(\beta_{16}) \sim N(0.84, 0.1)$ $g(\beta_{26}) \sim N(0, 0.1)$
	$Pr(Y_{i6} = 1 D_i = 0) = \emptyset(\alpha_{16})$	$g(\alpha_{16}) \sim N(-3.09, 0.01)$	$g(\alpha_{16}) \sim N(-3.09, 0.01)$	$g(\alpha_{16}) \sim N(-3.09, 0.01)$

63 D – Disease (PTB), Y_1 – any TB symptom, Y_2 – Radiologist conclusion, Y_3 – CAD4TBv5≥53 Y_4 – CAD4TBv6≥53, Y_5 –
64 Xpert Ultra, Y_6 – Culture, “-” implies the parameter is not included (i.e set to zero) in the model, Model 0 – Based
65 on the assumption of conditional independence, Model 1 – Accounts for conditional dependence between
66 radiologist conclusion, CAD4TBv5≥53 and CAD4TBv6≥53 and between Xpert Ultra and culture among the PTB cases
67 and allows conditional independence between all the diagnostic tests among non-PTB cases, Model 2 – Accounts
68 for conditional dependence between radiologist conclusion, CAD4TBv5≥53 and CAD4TBv6≥53 and between Xpert
69 Ultra and culture among the PTB cases and conditional dependence between any TB symptom, radiologist
70 conclusion, CAD4TBv5≥53 and CAD4TBv6≥53 among non-PTB cases
71

72 Table S3: Prior distributions for the parameters in the probit regression models for Vukuzazi data

Model structure		Model 3
D	$Pr(D = 1) = \emptyset(\omega)$	$g(\omega) \sim N(-3, 0.1)$
Y_1	$Pr(Y_{i1} = 1 D_i = 1) = \emptyset(\beta_{11})$	$g(\beta_{11}) \sim N(0, 0.1)$
	$Pr(Y_{i1} = 1 D_i = 0) = \emptyset(\alpha_{11})$	$g(\alpha_{11}) \sim N(0, 10)$
Y_2	$Pr(Y_{i2} = 1 Y_{i1}, D_i=1) = \emptyset(\beta_{12})$	$g(\beta_{12}) \sim N(0, 0.1)$
	$Pr(Y_{i2} = 1 Y_{i1}, D_i=0) = \emptyset(\alpha_{12} + \alpha_{22}y_{i1})$	$g(\alpha_{12}) \sim N(0, 10)$ $g(\alpha_{22}) \sim N(0, 10)$
Y_3	$Pr(Y_{i3} = 1 Y_{i2}, D_i=1) = \emptyset(\beta_{13} + \beta_{23}y_{i2})$	$g(\beta_{13}) \sim N(0, 0.1)$ $g(\beta_{23}) \sim N(0, 0.1)$
	$Pr(Y_{i3} = 1 Y_{i1}, Y_{i2}, D_i=0) = \emptyset(\alpha_{13} + \alpha_{23}y_{i1} + \alpha_{33}y_{i2})$	$g(\alpha_{13}) \sim N(0, 10)$ $g(\alpha_{23}) \sim N(0, 10)$ $g(\alpha_{33}) \sim N(0, 10)$
Y_4	$Pr(Y_{i4} = 1 Y_{i2}, Y_{i3}, D_i=1) = \emptyset(\beta_{14} + \beta_{24}y_{i2} + \beta_{34}y_{i3})$	$g(\beta_{14}) \sim N(0, 0.1)$ $g(\beta_{24}) \sim N(0, 0.1)$ $g(\beta_{34}) \sim N(0, 0.1)$
	$Pr(Y_{i4} = 1 Y_{i1}, Y_{i2}, Y_{i3}, D_i=0) = \emptyset(\alpha_{14} + \alpha_{24}y_{i1} + \alpha_{34}y_{i2} + \alpha_{44}y_{i3})$	$g(\alpha_{14}) \sim N(0, 10)$ $g(\alpha_{24}) \sim N(0, 10)$ $g(\alpha_{34}) \sim N(0, 10)$ $g(\alpha_{44}) \sim N(0, 10)$
Y_5	$Pr(Y_{i5} = 1 Y_{i2}, Y_{i3}, Y_{i4}, D_i=1) = \emptyset(\beta_{15} + \beta_{25}y_{i2} + \beta_{35}y_{i3} + \beta_{45}y_{i4})$	$g(\beta_{15}) \sim N(0, 0.1)$ $g(\beta_{25}) \sim N(0, 0.1)$ $g(\beta_{35}) \sim N(0, 0.1)$ $g(\beta_{45}) \sim N(0, 0.1)$
	$Pr(Y_{i5} = 1 D_i=0) = \emptyset(\alpha_{15})$	$g(\alpha_{15}) \sim N(-1.88, 0.01)$
Y_6	$Pr(Y_{i6} = 1 Y_{i2}, Y_{i3}, Y_{i4}, Y_{i5}, D_i=1) = \emptyset(\beta_{16} + \beta_{26}y_{i2} + \beta_{36}y_{i3} + \beta_{46}y_{i4} + \beta_{56}y_{i5})$	$(\beta_{16}) \sim N(0.84, 0.1)$ $g(\beta_{26}) \sim N(0, 0.1)$ $g(\beta_{36}) \sim N(0, 0.1)$ $g(\beta_{46}) \sim N(0, 0.1)$ $g(\beta_{56}) \sim N(0, 0.1)$
	$Pr(Y_{i6} = 1 D_i=0) = \emptyset(\alpha_{16})$	$g(\alpha_{16}) \sim N(-3.09, 0.01)$

73 D – Disease (PTB), Y_1 – any TB symptom, Y_2 – Radiologist conclusion, Y_3 – CAD4TBv5 \geq 53 Y_4 – CAD4TBv6 \geq 53, Y_5 –
 74 Xpert Ultra, Y_6 – Culture, Model 3 – Accounts for conditional dependence between all the diagnostic tests except
 75 any TB symptom among the PTB cases and dependence between any TB symptom, radiologist conclusion,
 76 CAD4TBv5 \geq 53 and CAD4TBv6 \geq 53 among non-PTB cases.

77

78

79

80

81

82

83

84

85 Table S4: Prior distributions for the parameters in the probit regression models for Vukuzazi data

Model structure		Model 4
D	$Pr(D = 1) = \emptyset(\omega)$	$g(\omega) \sim N(-3, 0.1)$
Y_1	$Pr(Y_{i1} = 1 D_i = 1) = \emptyset(\beta_{11})$	$g(\beta_{11}) \sim N(0, 0.1)$
	$Pr(Y_{i1} = 1 D_i = 0) = \emptyset(\alpha_{11})$	$g(\alpha_{11}) \sim N(0, 10)$
Y_2	$Pr(Y_{i2} = 1 Y_{i1}, D_i=1) = \emptyset(\beta_{12} + \beta_{22}y_{i1})$	$g(\beta_{12}) \sim N(0, 0.1)$ $g(\beta_{22}) \sim N(0, 0.1)$
	$Pr(Y_{i2} = 1 Y_{i1}, D_i=0) = \emptyset(\alpha_{12} + \alpha_{22}y_{i1})$	$g(\alpha_{12}) \sim N(0, 10)$ $g(\alpha_{22}) \sim N(0, 10)$
Y_3	$Pr(Y_{i3} = 1 Y_{i1}, Y_{i2}, D_i=1) = \emptyset(\beta_{13} + \beta_{23}y_{i1} + \beta_{33}y_{i2})$	$g(\beta_{13}) \sim N(0, 0.1)$ $g(\beta_{23}) \sim N(0, 0.1)$ $g(\beta_{33}) \sim N(0, 0.1)$
	$Pr(Y_{i3} = 1 Y_{i1}, Y_{i2}, D_i=0) = \emptyset(\alpha_{13} + \alpha_{23}y_{i1} + \alpha_{33}y_{i2})$	$g(\alpha_{13}) \sim N(0, 10)$ $g(\alpha_{23}) \sim N(0, 10)$ $g(\alpha_{33}) \sim N(0, 10)$
Y_4	$Pr(Y_{i4} = 1 Y_{i1}, Y_{i2}, Y_{i3}, D_i=1) = \emptyset(\beta_{14} + \beta_{24}y_{i1} + \beta_{34}y_{i2} + \beta_{44}y_{i3})$	$g(\beta_{14}) \sim N(0, 0.1)$ $g(\beta_{24}) \sim N(0, 0.1)$ $g(\beta_{34}) \sim N(0, 0.1)$ $g(\beta_{44}) \sim N(0, 0.1)$
	$Pr(Y_{i4} = 1 Y_{i1}, Y_{i2}, Y_{i3}, D_i=0) = \emptyset(\alpha_{14} + \alpha_{24}y_{i1} + \alpha_{34}y_{i2} + \alpha_{44}y_{i3})$	$g(\alpha_{14}) \sim N(0, 10)$ $g(\alpha_{24}) \sim N(0, 10)$ $g(\alpha_{34}) \sim N(0, 10)$ $g(\alpha_{44}) \sim N(0, 10)$
Y_5	$Pr(Y_{i5} = 1 Y_{i1}, Y_{i2}, Y_{i3}, Y_{i4}, D_i=1) = \emptyset(\beta_{15} + \beta_{25}y_{i1} + \beta_{35}y_{i2} + \beta_{45}y_{i3} + \beta_{55}y_{i4})$	$g(\beta_{15}) \sim N(0, 0.1)$ $g(\beta_{25}) \sim N(0, 0.1)$ $g(\beta_{35}) \sim N(0, 0.1)$ $g(\beta_{45}) \sim N(0, 0.1)$ $g(\beta_{55}) \sim N(0, 0.1)$
	$Pr(Y_{i5} = 1 D_i=0) = \emptyset(\alpha_{15})$	$g(\alpha_{15}) \sim N(-1.88, 0.01)$
Y_6	$Pr(Y_{i6} = 1 Y_{i1}, Y_{i2}, Y_{i3}, Y_{i4}, Y_{i5}, D_i=1)$ $= \emptyset(\beta_{16} + \beta_{26}y_{i1} + \beta_{36}y_{i2} + \beta_{46}y_{i3} + \beta_{56}y_{i4} + \beta_{66}y_{i5})$	$g(\beta_{16}) \sim N(0.84, 0.1)$ $g(\beta_{26}) \sim N(0, 0.1)$ $g(\beta_{36}) \sim N(0, 0.1)$ $g(\beta_{46}) \sim N(0, 0.1)$ $g(\beta_{56}) \sim N(0, 0.1)$ $g(\beta_{66}) \sim N(0, 0.1)$
	$Pr(Y_{i6} = 1 D_i=0) = \emptyset(\alpha_{16})$	$g(\alpha_{16}) \sim N(-3.09, 0.01)$

86 D – Disease (PTB), Y_1 – any TB symptom, Y_2 – Radiologist conclusion, Y_3 – CAD4TBv5≥53 Y_4 – CAD4TBv6≥53, Y_5 –
87 Xpert Ultra, Y_6 – Culture, Model 4 – Accounts for conditional dependence between all the diagnostic tests among
88 the PTB cases and conditional dependence between any TB symptom, radiologist conclusion, CAD4TBv5≥53 and
89 CAD4TBv6≥53 among non-PTB cases

91 Table S5: Prior distributions for the parameters in the probit regression models for Vukuzazi data

	Model structure	Model 2 with covariates
D	$Pr(D = 1 X_{i1}, X_{i2}, X_{i3}) = \emptyset \left(\begin{array}{c} \omega_0 + \omega_1 x_{i3} + \omega_2 x_{i2} + \omega_3 I(x_{i1} = 2) + \\ \omega_4 I(x_{i1} = 3) + \omega_5 I(x_{i1} = 4) \end{array} \right)$	$g(\omega_0) \sim N(-5, 0.1)$ $g(\omega_1) \sim N(0, 0.01), \dots,$ $g(\omega_5) \sim N(0, 0.01)$
Y_1	$Pr(Y_{i1} = 1 X_{i1}, X_{i2}, X_{i3}, D_i = 1) = \emptyset \left(\begin{array}{c} \beta_{11} + \beta_{21} x_{i3} + \beta_{31} x_{i2} + \beta_{41} I(x_{i1} = 2) + \\ \beta_{51} I(x_{i1} = 3) + \beta_{61} I(x_{i1} = 4) \end{array} \right)$	$g(\beta_{11}) \sim N(0, 10)$ $g(\beta_{21}) \dots g(\beta_{61}) \sim N(0, 1)$
	$Pr(Y_{i1} = 1 X_{i1}, X_{i2}, X_{i3}, D_i = 0) = \emptyset \left(\begin{array}{c} \alpha_{11} + \alpha_{21} x_{i3} + \alpha_{31} x_{i2} + \alpha_{41} I(x_{i1} = 2) + \\ \alpha_{51} I(x_{i1} = 3) + \alpha_{61} I(x_{i1} = 4) \end{array} \right)$	$g(\alpha_{11}) \sim N(0, 10)$ $g(\alpha_{21}) \dots g(\alpha_{61}) \sim N(0, 1)$
Y_2	$Pr(Y_{i2} = 1 X_{i1}, X_{i2}, X_{i3}, D_i = 1) = \emptyset \left(\begin{array}{c} \beta_{12} + \beta_{22} x_{i3} + \beta_{32} x_{i2} + \beta_{42} I(x_{i1} = 2) + \\ \beta_{52} I(x_{i1} = 3) + \beta_{62} I(x_{i1} = 4) \end{array} \right)$	$g(\beta_{12}) \dots g(\beta_{62}) \sim N(0, 1)$
	$Pr(Y_{i2} = 1 Y_{i1}, X_{i1}, X_{i2}, X_{i3}, D_i = 0) = \emptyset \left(\begin{array}{c} \alpha_{12} + \alpha_{22} y_{i1} + \alpha_{32} x_{i3} + \alpha_{42} x_{i2} + \alpha_{52} I(x_{i1} = 2) + \\ \alpha_{62} I(x_{i1} = 3) + \alpha_{72} I(x_{i1} = 4) \end{array} \right)$	$g(\alpha_{12}), g(\alpha_{22}) \sim N(0, 10)$ $g(\alpha_{32}) \dots g(\alpha_{72}) \sim N(0, 1)$
Y_3	$Pr(Y_{i3} = 1 Y_{i2}, X_{i1}, X_{i2}, X_{i3}, D_i = 1) = \emptyset \left(\begin{array}{c} \beta_{13} + \beta_{23} y_{i2} + \beta_{33} x_{i3} + \beta_{43} x_{i2} + \beta_{53} I(x_{i1} = 2) + \\ \beta_{63} I(x_{i1} = 3) + \beta_{73} I(x_{i1} = 4) \end{array} \right)$	$g(\beta_{13}) \dots g(\beta_{73}) \sim N(0, 1)$
	$Pr(Y_{i3} = 1 Y_{i1}, Y_{i2}, X_{i1}, X_{i2}, X_{i3}, D_i = 0) = \emptyset \left(\begin{array}{c} \alpha_{13} + \alpha_{23} y_{i1} + \alpha_{33} y_{i2} + \alpha_{43} x_{i3} + \alpha_{53} x_{i2} + \\ \alpha_{63} I(x_{i1} = 2) + \alpha_{73} I(x_{i1} = 3) + \alpha_{83} I(x_{i1} = 4) \end{array} \right)$	$g(\alpha_{13}) \dots g(\alpha_{33}) \sim N(0, 10)$ $g(\alpha_{43}) \dots g(\alpha_{83}) \sim N(0, 1)$
Y_4	$Pr(Y_{i4} = 1 Y_{i2}, Y_{i3}, X_{i1}, X_{i2}, X_{i3}, D_i = 1) = \emptyset \left(\begin{array}{c} \beta_{14} + \beta_{24} y_{i2} + \beta_{34} y_{i3} + \beta_{44} x_{i3} + \beta_{54} x_{i2} + \\ \beta_{64} I(x_{i1} = 2) + \beta_{74} I(x_{i1} = 3) + \beta_{84} I(x_{i1} = 4) \end{array} \right)$	$g(\beta_{14}) \dots g(\beta_{84}) \sim N(0, 1)$
	$Pr(Y_{i4} = 1 Y_{i1}, Y_{i2}, Y_{i3}, X_{i1}, X_{i2}, X_{i3}, D_i = 0) = \emptyset \left(\begin{array}{c} \alpha_{14} + \alpha_{24} y_{i1} + \alpha_{34} y_{i2} + \alpha_{44} y_{i3} + \alpha_{54} x_{i3} + \alpha_{64} x_{i2} + \\ \alpha_{74} I(x_{i1} = 2) + \alpha_{84} I(x_{i1} = 3) + \alpha_{94} I(x_{i1} = 4) \end{array} \right)$	$g(\alpha_{14}) \dots g(\alpha_{44}) \sim N(0, 10)$ $g(\alpha_{54}) \dots g(\alpha_{94}) \sim N(0, 1)$
Y_5	$Pr(Y_{i5} = 1 X_{i1}, X_{i2}, X_{i3}, D_i = 1) = \emptyset \left(\begin{array}{c} \beta_{15} + \beta_{25} x_{i3} + \beta_{35} x_{i2} + \beta_{45} I(x_{i1} = 2) + \beta_{55} \\ I(x_{i1} = 3) + \beta_{65} I(x_{i1} = 4) \end{array} \right)$	$g(\beta_{15}) \dots g(\beta_{65}) \sim N(0, 1)$
	$Pr(Y_{i5} = 1 D_i = 0) = \emptyset(\alpha_{15})$	$g(\alpha_{15}) \sim N(-1.88, 0.01)$
Y_6	$Pr(Y_{i6} = 1 Y_{i5}, X_{i1}, X_{i2}, X_{i3}, D_i = 1) = \emptyset \left(\begin{array}{c} \beta_{16} + \beta_{26} y_{i5} + \beta_{36} x_{i3} + \beta_{46} x_{i2} + \beta_{56} I(x_{i1} = 2) + \\ \beta_{66} I(x_{i1} = 3) + \beta_{76} I(x_{i1} = 4) \end{array} \right)$	$g(\beta_{16}) \sim N(0.84, 0.1)$ $g(\beta_{26}) \dots g(\beta_{76}) \sim N(0, 1)$
	$Pr(Y_{i6} = 1 D_i = 0) = \emptyset(\alpha_{16})$	$g(\alpha_{16}) \sim N(-3.09, 0.01)$

92 D – Disease (PTB), Y_1 – any TB symptom, Y_2 – Radiologist conclusion, Y_3 – CAD4TBv5 ≥ 53 Y_4 – CAD4TBv6 ≥ 53 , Y_5 –
93 Xpert Ultra, Y_6 – Culture; Model 2 – Accounts for conditional dependence between radiologist conclusion,
94 CAD4TBv5 ≥ 53 and CAD4TBv6 ≥ 53 and between Xpert Ultra and culture among the PTB cases and conditional
95 dependence between any TB symptom, radiologist conclusion, CAD4TBv5 ≥ 53 and CAD4TBv6 ≥ 53 among non-PTB
96 cases, adjusted for covariates (age, sex and HIV status).

97 In Table S5, D denotes disease (PTB), Y_1, Y_2, Y_3, Y_4, Y_5 and Y_6 denotes any TB symptom , Radiologist conclusion,
98 CAD4TBv5 ≥ 53 , CAD4TBv6 ≥ 53 , Xpert Ultra and Culture respectively. X_1 denotes age (categorical variable), X_2
99 denotes sex (Male/Female) and X_3 denotes HIV status (+/-)

100 The choice of the informative prior for the parameters of the probit regression models was adapted based on the
101 expert opinion and previously published material. This was chosen in order to yield a posterior distribution that
102 spans the range of plausible values for the parameter.

103 The joint probability of random variables Y and X_1, X_2, X_3 given by $Pr(Y, X_1, X_2, X_3)$ can be expressed using chain
104 rule of conditional probabilities as $Pr(X_1)Pr(X_2|X_1)Pr(X_3|X_1, X_2)Pr(Y|X_1, X_2, X_3)$. Where Y is either the disease
105 status or diagnostic test and X_1 – Age (four level categorical variable: 15-19 years, 30-49 years, 50-69 years, ≥ 70
106 years) with reference category as 15-19 years, X_2 - Sex (Male/Female), X_3 – HIV status (+/-). The conditional
107 probabilities were computed using probit regression models with priors from Gaussian distribution. The unknown
108 parameters of X_1, X_2 and X_3 in the model $Pr(Y|X_1, X_2, X_3)$ are assigned priors from $N(0,10)$ (Table S5). The
109 unknown parameters of X_1 and X_2 in the models $Pr(X_2|X_1)$ and $Pr(X_3|X_1, X_2)$ are assigned priors from $N(0,10)$.
110 To model $Pr(X_1)$ we assigned non-informative dirichlet prior, $Dir(\vartheta_1 = 1, \vartheta_2 = 1, \vartheta_3 = 1, \vartheta_4 = 1)$, to the
111 parameters of the multinomial distribution.


112 **3. Computer-Aided Detection for TB (CAD4TB) Threshold**

113 Given all the diagnostic tests in use are imperfect, the true TB status is unknown. This is the complexity in diagnostic
114 studies without a perfect reference standard. However, as alluded to in the background of the abstract and in the
115 introduction, this problem can be handled using latent class analysis, a statistical methodology that has been in use
116 over the past four decades in many disciplines but scarcely used in the field of infectious diseases, including the field
117 of TB. This method identifies unobserved mutually exclusive subgroups in the population using information from the
118 measured subject characteristics. In our case, using the information (test results) from all the imperfect diagnostic
119 tests the model can stochastically tease out the TB and non-TB cases. Consequently, using the derived subgroups,
120 the sensitivity and specificity of the tests can be calculated.

121 CAD4TB thresholds were determined based on secondary analysis of data from the community-based multi-
122 morbidity survey in KwaZulu-Natal, South Africa (“Vukuzazi” study) using Bayesian latent class analysis. In this survey,
123 the digital chest X-ray images were interpreted using CAD4TB version 5 (CAD4TBv5) and CAD4TBv6. The thresholds
124 for both CAD4TBv5 and CAD4TBv6 were determined by performing LCA to estimate the sensitivity and specificity of
125 CAD4TB at integer thresholds S_k , $k = 2, 3, \dots, K-1$, for K distinct CAD4TB scores. Thus, there were $K-2$ models fit and
126 for each model, the estimates of pulmonary TB prevalence and diagnostic test sensitivity and specificity were
127 obtained. The estimates of sensitivity and specificity for CAD4TB were used to construct a receiver operating
128 characteristic (ROC) curve to help identify a plausible CAD4TB cut-off score.

129 Determination of CAD4TB cut-off scores proceeded by first fitting a two-class latent class model with any TB
130 symptom, radiologist interpretation (chest X-ray abnormality suggestive of active TB), $CAD4TBv5 \geq S_k$, Xpert Ultra
131 (excluding trace) and culture. Using the estimates of sensitivity and specificity for CAD4TBv5 obtained from the fitted
132 models we constructed a ROC curve and determined CAD4TBv5 threshold, say S_{t1} . Next, we fitted a two-class latent
133 class model with any TB symptom, radiologist interpretation (chest X-ray abnormality suggestive of active TB),
134 $CAD4TBv5 \geq S_{t1}$, $CAD4TBv6 \geq S_k$, Xpert Ultra (excluding trace) and culture, where we now set threshold for CAD4TBv5
135 at S_{t1} . Again, using the same approach, we determined the threshold for CAD4TBv6, say S_{t2} . For both CAD4TBv5 and
136 CAD4TBv6, we aimed at a threshold score that produced sensitivity and specificity estimates close to 80%. The cut-
137 off values were 53 for CAD4TBv5 and 52 for CAD4TBv6 (Fig S1). Nonetheless, we opted for the same cut-off of 53 for
138 both CAD4TBv5 and CAD4TBv6 based on the lowess smoother that revealed overlap of the two curves at around
139 80% for both the sensitivity and specificity for CAD4TBv5 and CAD4TBv6. The cut-off score of 53 yielded a sensitivity
140 of 83% and a specificity of 80% for CAD4TBv5. In the model that included $CAD4TBv5 \geq 53$ and CAD4TBv6 the threshold
141 score of 52 for CAD4TBv6 yielded a sensitivity of 84% and a specificity of 81%. While a threshold score of 53 for
142 CAD4TBv6 yielded a sensitivity and specificity of 80% and 83% respectively (Fig S1). This is no surprise given the
143 distribution of the difference in scores between the two versions of CAD4TB that is centered around zero (Fig S2).
144 Fig S1 shows the receiver operating characteristic (ROC) curves of the estimates of sensitivity and specificity for
145 CAD4TBv5 and CAD4TBv6.


ROC curve for CAD4TB version 5 and version 6



146

147 Fig S1: Receiver operating characteristic curves depicting the cut-off values used in the final latent class models

148 With these CAD4TB thresholds defined, we fitted a final model with any TB symptom, radiologist interpretation
149 (chest X-ray abnormality suggestive of active TB), $CAD4TBv5 \geq S_{t1}$, $CAD4TBv6 \geq S_{t2}$, Xpert Ultra (excluding trace) and
150 culture to estimate PTB prevalence, and diagnostic test sensitivity and specificity of the six diagnostic tests. We
151 repeated the same analysis with chest X-ray abnormality suggestive of active TB replaced by any chest X-ray
152 abnormality.



153

154 Fig S2: Distribution of difference in CAD4TB scores between version 6 and version 5


155

156 Fig S3 shows a scatter plot of CAD4TBv5 and CAD4TBv6 scores. The scatter plot reveals some trend in the scores.

157 However, it is imperative to understand that the two devices are used to evaluate chest X-ray images of the same

158 person. Therefore, they are paired. From the scatter plot, the positive correlation between version 6 and version 5

159 is not sufficiently strong to result in strong dependencies between the two versions in the model.



160

161 Fig S3: Scatter plot of CAD4TB version 5 and CAD4TB version 6 scores

162

163

164 **4. Supplementary Tables**

165 Table S7 presents results of four models. The results of Model 1, Model 2 and Model 3 were already presented in
 166 the main document but shown here to aid comparison with Model 4. These findings suggest that conditional
 167 dependence between TST and radiography among the children without CPTB cannot be ignored.

168 Table S6: Posterior median and 95% credible intervals (95% Crl) of the prevalence and diagnostic test accuracy of the parameters of childhood pulmonary
 169 tuberculosis dataset

		Model 0	Model 1	Model 2	Model 3	Model 4
Test	Parameter	Median (95% Crl)				
TST	Prevalence	16.3 (13.6, 19.3)	21.6 (15.6, 28.6)	18.4 (14.7, 26.4)	18.9 (15.1, 27.0)	19.9 (15.4, 29.7)
	Sensitivity	69.2 (60.5, 76.9)	73.2 (61.8, 82.4)	68.3 (58.5, 79.9)	69.5 (59.4, 81.5)	70.5 (60.2, 83.0)
Rad.	Specificity	62.3 (58.4, 66.1)	65.2 (59.6, 71.8)	62.7 (58.5, 69.6)	63.1 (58.8, 70.4)	63.7 (59.2, 72.8)
	Sensitivity	66.0 (57.1, 74.1)	65.1 (56.1, 73.8)	64.5 (55.5, 73.3)	60.1 (42.5, 72.2)	62.7 (51.8, 76.8)
SMM	Specificity	73.1 (69.5, 76.5)	74.8 (70.5, 79.2)	73.2 (69.4, 77.9)	72.2 (67.8, 76.5)	73.7 (69.4, 79.9)
	Sensitivity	33.8 (25.5, 42.5)	24.3 (16.7, 34.8)	28.4 (18.7, 37.6)	28.4 (19.0, 37.2)	26.7 (16.7, 36.4)
Xpert	Specificity	99.9 (99.5, 100)	99.9 (99.5, 100)	99.9 (99.5, 100)	99.9 (99.5, 100)	99.9 (99.5, 100)
	Sensitivity	74.8 (66.3, 82.5)	59.1 (44.2, 75.7)	69.4 (47.8, 78.4)	70.3 (47.9, 79.5)	66.3 (43.2, 79.1)
Culture	Specificity	98.2 (97.0, 99.3)	98.7 (97.1, 99.9)	98.7 (97.2, 99.9)	99.2 (97.5, 100)	99.0 (97.2, 100)
	Sensitivity	99.9 (91.0, 100)	75.3 (56.9, 97.2)	88.0 (61.8, 98.4)	86.4 (60.3, 98.5)	82.7 (55.1, 98.2)
	Deviance	183.7	104.7	102.1	101.7	107.8
	RMSE	42.4	38.0	12.0	9.1	32.9

170 Model 0 – Based on the assumption of conditional independence

171 Model 1 – Based on the expert opinion as detailed in [3]. The model accounts for conditional dependence between all the diagnostic tests except radiography
 172 among children with CPTB and conditional independence between all the diagnostic tests among children without CPTB

173 Model 2 – The model accounts for conditional dependence between all the diagnostic tests except radiography among children with CPTB and conditional
 174 dependence between TST and radiography among children without CPTB

175 Model 3 – Accounts for conditional dependence between all the diagnostic tests among children with CPTB and conditional dependence between TST and
 176 radiography among children without CPTB

177 Model 4 – Accounts for conditional dependence between all the diagnostic tests among children with CPTB and allows conditional independence between all
 178 the diagnostic tests among children without CPTB

179 TST – Tuberculin skin test, Rad. – Radiography, SMM – Sputum smear microscopy, Xpert – Xpert MTB/RIF

180 RMSE – Root mean squared error deviations. This is calculated as the square root of the sum of squared differences between the observed frequencies and the
 181 predicted frequencies. It shows how good the model is in explaining the variability in the data

182 Note model 3 seems to do better prediction compared to model 1 although model 1 seems to best fit the data. This may be explained by the fact that model 3
 183 accounts for dependence between radiography and other diagnostic tests among the true CPTB cases. Hence extra penalty

184 Crl – Credible Intervals

185 Table S7: Distribution of the number of participants included in LCA by age, sex and HIV status

		Age (Years)				
		15 – 29 years	30 – 49 years	50 – 69 years	≥ 70 years	Total
Male	HIV +	56 (8.9%)	235 (48.4%)	148 (29.0%)	18 (9.6%)	457 (25.2%)
	HIV -	573 (91.1%)	251 (51.6%)	363 (71.0%)	169 (90.4%)	1356 (74.8%)
	Total	629 (34.7%)	486 (26.8%)	511 (28.2%)	187 (10.3%)	1813 (100%)
Female	HIV +	140 (26.6%)	507 (63.0%)	355 (29.3%)	37 (6.1%)	1039 (33.0%)
	HIV -	387 (73.4%)	298 (37.0%)	857 (70.7%)	566 (93.9%)	2108 (67.0%)
	Total	527 (16.7%)	805 (25.6%)	1212 (38.5%)	603 (19.2%)	3147 (100%)
Total	HIV +	196 (17.0%)	742 (57.5%)	503 (29.2%)	55 (7.0%)	1496 (30.2%)
	HIV -	960 (83.0%)	549 (42.5%)	1220 (70.8%)	735 (93.0%)	3464 (69.8%)
	Total	1156 (23.3%)	1291 (26.0%)	1723 (34.7%)	790 (15.9%)	4960 (100%)

186

187 Table S8: Posterior median and 95% credible intervals (95% CrI) of the age, sex and HIV adjusted PTB prevalence and diagnostic test sensitivity and specificity
 188 among male individuals in Vukuzazi dataset

			15 – 29 years	30 – 49 years	50 – 69 years	≥70 years
Group	Test	Parameter	Median (95% CrI)	Median (95% CrI)	Median (95% CrI)	Median (95% CrI)
HIV+ Male		Prevalence	1.5 (0.8, 2.4)	1.6 (0.9, 2.7)	1.9 (1.1, 3.2)	1.6 (0.8, 3.0)
	Any TB symptom	Sensitivity	28.1 (12.0, 51.2)	22.2 (7.2, 46.0)	27.8 (11.0, 50.1)	26.7 (7.6, 55.3)
		Specificity	82.3 (78.8, 85.4)	84.4 (81.6, 87.0)	84.4 (81.3, 87.2)	83.9 (79.7, 87.6)
	Radiologist conclusion [‡]	Sensitivity	90.2 (72.9, 97.7)	90.8 (72.8, 98.3)	94.9 (82.0, 99.2)	93.2 (74.0, 99.1)
		Specificity	77.8 (74.1, 81.4)	54.8 (51.1, 58.6)	44.3 (40.2, 48.5)	37.2 (32.0, 42.6)
	CAD4TBv5≥53	Sensitivity	86.4 (67.3, 96.2)	88.2 (67.5, 97.6)	88.6 (70.1, 97.3)	88.6 (65.8, 97.9)
		Specificity	87.3 (84.0, 90.2)	68.7 (65.1, 72.4)	56.3 (51.7, 60.7)	37.5 (32.0, 43.3)
	CAD4TBv6≥53	Sensitivity	83.3 (63.7, 94.7)	83.7 (60.8, 96.0)	86.6 (66.8, 96.6)	85.3 (59.9, 96.9)
		Specificity	89.8 (86.7, 92.3)	69.9 (66.2, 73.5)	57.0 (52.5, 61.6)	41.2 (35.7, 47.0)
	Xpert Ultra [†]	Sensitivity	65.1 (40.6, 85.3)	70.1 (42.7, 89.5)	69.9 (45.5, 88.0)	62.5 (31.9, 87.1)
		Specificity	99.4 (99.1, 99.6)	99.4 (99.1, 99.6)	99.4 (99.1, 99.6)	99.4 (99.1, 99.6)
	Culture	Sensitivity	76.7 (52.0, 94.1)	76.7 (47.7, 95.8)	71.1 (44.8, 92.9)	81.4 (52.8, 96.8)
		Specificity	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)
HIV- Male		Prevalence	0.9 (0.5, 1.4)	1.0 (0.6, 1.7)	1.2 (0.7, 2.0)	1.0 (0.5, 1.8)
	Any TB symptom	Sensitivity	26.1 (12.0, 44.6)	20.2 (6.4, 42.3)	25.5 (10.5, 47.1)	24.8 (7.9, 49.7)
		Specificity	81.9 (79.2, 84.3)	84.0 (81.1, 86.6)	84.0 (81.6, 86.3)	83.5 (80.1, 86.3)
	Radiologist conclusion [‡]	Sensitivity	83.4 (66.8, 93.8)	84.2 (63.2, 95.8)	90.5 (74.7, 97.7)	88.1 (67.3, 97.3)
		Specificity	85.9 (83.6, 88.1)	66.6 (63.0, 70.1)	56.6 (53.3, 60.0)	49.3 (45.0, 53.6)
	CAD4TBv5≥53	Sensitivity	82.5 (64.9, 93.7)	84.8 (63.0, 96.2)	85.5 (65.4, 96.1)	85.2 (63.2, 96.6)
		Specificity	91.2 (89.2, 93.1)	76.2 (72.7, 79.5)	64.8 (61.4, 68.2)	46.2 (41.7, 50.7)
	CAD4TBv6≥53	Sensitivity	80.8 (62.5, 92.7)	81.5 (58.3, 94.7)	84.8 (65.2, 95.6)	83.2 (60.0, 95.7)
		Specificity	94.4 (92.8, 95.8)	80.0 (76.7, 83.0)	69.0 (65.6, 72.2)	53.9 (49.4, 58.3)
	Xpert Ultra [†]	Sensitivity	69.3 (48.8, 85.3)	73.7 (49.0, 90.7)	73.5 (51.5, 89.6)	66.8 (39.2, 87.8)
		Specificity	99.4 (99.1, 99.6)	99.4 (99.1, 99.6)	99.4 (99.1, 99.6)	99.4 (99.1, 99.6)
	Culture	Sensitivity	78.2 (58.4, 92.9)	78.1 (51.6, 95.2)	72.6 (48.6, 92.5)	82.6 (58.1, 96.2)
		Specificity	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)

‡ - Any chest X-ray abnormality, † - Excluding trace

189 Table S9: Posterior median and 95% credible intervals (95% CrI) of the age, sex and HIV adjusted PTB prevalence and diagnostic test sensitivity and specificity
 190 among female individuals in Vukuzazi dataset

Group	Test	Parameter	15 – 29 years	30 – 49 years	50 – 69 years	≥70 years
HIV+ Female		Prevalence	0.9 (0.5, 1.5)	1.0 (0.5, 1.7)	1.2 (0.6, 2.0)	1.0 (0.5, 1.8)
	Any TB symptom	Sensitivity	30.2 (14.8, 51.4)	24.1 (9.1, 46.8)	29.8 (12.5, 52.3)	28.9 (9.5, 55.7)
		Specificity	81.4 (77.8, 84.5)	83.6 (81.1, 85.9)	83.6 (80.9, 85.9)	83.0 (79.3, 86.4)
	Radiologist conclusion [‡]	Sensitivity	84.9 (67.3, 94.8)	85.7 (65.7, 96.3)	91.6 (74.8, 98.2)	89.2 (67.6, 97.9)
		Specificity	84.2 (81.1, 86.9)	63.8 (60.7, 66.9)	53.6 (50.2, 57.1)	46.3 (41.5, 51.0)
	CAD4TBv5≥53	Sensitivity	79.5 (60.4, 92.4)	81.8 (59.8, 95.3)	82.6 (61.5, 94.8)	82.4 (57.6, 95.8)
		Specificity	96.1 (94.7, 97.3)	86.8 (84.5, 88.9)	78.4 (75.4, 81.2)	62.1 (57.1, 66.9)
	CAD4TBv6≥53	Sensitivity	80.8 (61.9, 92.7)	81.5 (59.2, 94.7)	84.7 (65.1, 95.4)	83.2 (58.1, 95.8)
		Specificity	96.8 (95.5, 97.9)	86.9 (84.7, 89.0)	78.3 (75.3, 81.2)	64.8 (59.9, 69.5)
	Xpert Ultra [†]	Sensitivity	52.2 (31.4, 72.4)	57.4 (33.2, 79.8)	57.3 (32.8, 78.7)	49.3 (23.5, 76.3)
		Specificity	99.4 (99.1, 99.6)	99.4 (99.1, 99.6)	99.4 (99.1, 99.6)	99.4 (99.1, 99.6)
	Culture	Sensitivity	76.9 (55.5, 92.6)	77.1 (50.6, 94.5)	71.4 (45.6, 92.0)	81.5 (55.5, 96.1)
		Specificity	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)
HIV- Female		Prevalence	0.5 (0.3, 0.9)	0.6 (0.3, 1.0)	0.7 (0.4, 1.2)	0.6 (0.3, 1.1)
	Any TB symptom	Sensitivity	28.1 (15.4, 44.0)	22.2 (8.2, 43.4)	27.4 (11.9, 49.1)	26.6 (9.9, 50.5)
		Specificity	80.9 (78.1, 83.6)	83.2 (80.3, 85.8)	83.1 (81.0, 85.1)	82.6 (79.8, 85.2)
	Radiologist conclusion [‡]	Sensitivity	76.4 (60.8, 87.8)	77.5 (54.9, 91.6)	85.5 (66.8, 95.5)	82.1 (59.7, 94.7)
		Specificity	90.5 (88.6, 92.2)	74.6 (71.4, 77.7)	65.6 (62.9, 68.1)	58.5 (54.8, 62.0)
	CAD4TBv5≥53	Sensitivity	74.6 (57.5, 87.3)	77.4 (54.7, 92.5)	78.5 (56.6, 92.5)	78.1 (55.0, 93.0)
		Specificity	97.6 (96.8, 98.3)	91.0 (89.0, 92.7)	84.3 (82.3, 86.2)	70.2 (66.9, 73.3)
	CAD4TBv6≥53	Sensitivity	77.9 (61.8, 89.8)	78.8 (56.4, 93.0)	82.4 (62.4, 94.1)	80.7 (58.3, 94.0)
		Specificity	98.5 (97.9, 99.0)	92.5 (90.8, 94.1)	86.4 (84.5, 88.2)	75.7 (72.7, 78.5)
	Xpert Ultra [†]	Sensitivity	56.5 (40.0, 72.6)	61.9 (37.6, 82.3)	61.4 (38.5, 81.6)	53.7 (30.1, 77.2)
		Specificity	99.4 (99.1, 99.6)	99.4 (99.1, 99.6)	99.4 (99.1, 99.6)	99.4 (99.1, 99.6)
	Culture	Sensitivity	78.5 (61.9, 90.6)	78.5 (54.7, 93.8)	73.0 (48.8, 91.7)	82.8 (60.8, 95.2)
		Specificity	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)


‡ - Any chest X-ray abnormality, † - Excluding trace

191

192 **5. Supplementary Figures**193 **Model Diagnostics**

194 Trace plots for assessing mixing in the chains

195



196


197 Fig S4: Trace plots of parameters on the probit scale corresponding to prevalence (ω) and parameters of the probit
 198 regression models for conditional probabilities of diagnostic tests in the childhood pulmonary TB data analyzed
 199 using Model 2 presented in Table S1

200

201

202

203



204

205 Fig S5: Trace plots of parameters of probit regression model for pulmonary TB prevalence in Vukuzazi dataset
206 analyzed using Model 2 presented in Table S4

207


208

209

210

211

212



213


214 Fig S6: Trace plots of parameters of the probit regression model for conditional probability of any TB symptom
215 among the true PTB cases (β) and among the true non-PTB cases (α) in the Vukuzazi dataset analyzed using Model
216 2 presented in Table S4

217

218

219

220



221

222 Fig S7: Trace plots of parameters of the probit regression model for conditional probability of radiologist
223 conclusion (any chest X-ray abnormality) among the true PTB cases (β) and among the true non-PTB cases (α) in
224 the Vukuzazi dataset analyzed using Model 2 presented in Table S4

225

226


227

228

229

230

231



232

233 Fig S8: Trace plots of parameters of the probit regression model for conditional probability of CAD4TBv5 \geq 53 among
 234 the true PTB cases (β) and among the true non-PTB cases (α) in the Vukuzazi dataset analyzed using Model 2
 235 presented in Table S4

236

237


238

239

240

241


242



243

244 Fig S9: Trace plots of parameters of the probit regression model for conditional probability of CAD4TBv6 \geq 53 among
 245 the true PTB cases (β) and among the true non-PTB cases (α) in the Vukuzazi dataset analyzed using Model 2
 246 presented in Table S4

247



248

249 Fig S10: Trace plots of parameters of the probit regression model for conditional probability of Xpert Ultra and
 250 culture among the true PTB cases (β) and among the true non-PTB cases (α) in the Vukuzazi dataset analyzed using
 251 Model 2 presented in Table S4

252

253

254

255

256

257

258 6. Analysis scripts

259 Below is the Rjags script for model 2 used for analyzing childhood pulmonary TB data. The other models can be
 260 adapted from this model.

```

261 model2 <- function(){
262   #K is the number of columns in y
263   #The first column of y is 1s
264   #We have K-1 tests
265   ## likelihood -----
266   Freqobs[1:J] ~ dmulti(p[1:J],N)
267   for (j in 1:J) {    # Prob. of a combination of J test results
268     p[j] <- pi*prod(cp1[j,1:(K-1)]^y[j,2:K]*(1-cp1[j,1:(K-1)])^(1-y[j,2:K])) +
269       (1-pi)*prod(cp0[j,1:(K-1)]^y[j,2:K]*(1-cp0[j,1:(K-1)])^(1-y[j,2:K]))
270
271     cp1[j,1] = phi( inprod( y[j,c(1:1)], beta[1:1,1] ) ) #Modeling pr(y_1 = + | D=+)
272     cp1[j,2] = phi( inprod( y[j,c(1:2)], beta[1:2,2] ) ) #Modeling pr(y_2 = + | y_1, D=+)
273     cp1[j,3] = phi( inprod( y[j,c(1:3)], beta[1:3,3] ) ) #Modeling pr(y_3 = + | y_1, y_2, D=+)
274     cp1[j,4] = phi( inprod( y[j,c(1:4)], beta[1:4,4] ) ) #Modeling pr(y_4 = + | y_1, y_2, y_3, D=+)
275     cp1[j,5] = phi( inprod( y[j,c(1:5)], beta[1:5,5] ) ) #Modeling pr(y_5 = + | y_1, y_2, y_3, y_4, D=+)
276
277     #Predict conditional probabilities
278     jp1x[j,1] = y[j,2]*cp1[j,1] + (1-y[j,2])*(1-cp1[j,1])
279     jp1x[j,2] = y[j,3]*cp1[j,2] + (1-y[j,3])*(1-cp1[j,2])
280     jp1x[j,3] = y[j,4]*cp1[j,3] + (1-y[j,4])*(1-cp1[j,3])
281     jp1x[j,4] = y[j,5]*cp1[j,4] + (1-y[j,5])*(1-cp1[j,4])
282     jp1x[j,5] = y[j,6]*cp1[j,5] + (1-y[j,6])*(1-cp1[j,5])
283
284     cp0[j,1] = phi( inprod( y[j,c(1:1)], alpha[1:1,1] ) ) # Modeling pr(y_1 = + | D=-)
285     cp0[j,2] = phi( inprod( y[j,c(1:2)], alpha[1:2,2] ) ) # Modeling pr(y_2 = + | y_1, D=-)
286     cp0[j,3] = phi( inprod( y[j,c(1:3)], alpha[1:1,3] ) ) # Modeling pr(y_3 = + | y_1, y_2, D=-)
287     cp0[j,4] = phi( inprod( y[j,c(1:4)], alpha[1:1,4] ) ) # Modeling pr(y_4 = + | y_1, y_2, y_3, D=-)
288     cp0[j,5] = phi( inprod( y[j,c(1:5)], alpha[1:1,5] ) ) #Modeling pr(y_5 = + | y_1, y_2, y_3, y_4, D=-)
289
290     #Predict conditional probabilities
291     jp0x[j,1] = y[j,2]*cp0[j,1] + (1-y[j,2])*(1 - cp0[j,1])
292     jp0x[j,2] = y[j,3]*cp0[j,2] + (1-y[j,3])*(1 - cp0[j,2])
293     jp0x[j,3] = y[j,4]*cp0[j,3] + (1-y[j,4])*(1 - cp0[j,3])
294     jp0x[j,4] = y[j,5]*cp0[j,4] + (1-y[j,5])*(1 - cp0[j,4])
295     jp0x[j,5] = y[j,6]*cp0[j,5] + (1-y[j,6])*(1 - cp0[j,5])
296
297     jp1[j,1] = prod( jp1x[j,1] )
298     jp1[j,2] = prod( jp1x[j,1:2] )
299     jp1[j,3] = prod( jp1x[j,1:3] )
300     jp1[j,4] = prod( jp1x[j,1:4] )
301     jp1[j,5] = prod( jp1x[j,1:5] )
302
303     jp0[j,1] = prod( jp0x[j,1] )
304     jp0[j,2] = prod( jp0x[j,1:2] )
305     jp0[j,3] = prod( jp0x[j,3] )
306     jp0[j,4] = prod( jp0x[j,4] )
307     jp0[j,5] = prod( jp0x[j,5] )

```

```

308      }
309      #calculate the sensitivity and specificity
310      se[1] = sum( jp1[c(1:1), 1] )
311      se[2] = sum( jp1[c(1:2), 2] )
312      se[3] = sum( jp1[c(1:4), 3] )
313      se[4] = sum( jp1[c(1:8), 4] )
314      se[5] = sum( jp1[c(1:16), 5] )
315
316      sp[1] = 1 - sum( jp0[c(1:1), 1] )
317      sp[2] = 1 - sum( jp0[c(1:2), 2] )
318      sp[3] = 1 - sum( jp0[c(1:1), 3] )
319      sp[4] = 1 - sum( jp0[c(1:1), 4] )
320      sp[5] = 1 - sum( jp0[c(1:1), 5] )
321
322      pi <- phi(omega)
323
324      ## priors -----
325      for(g in 1:(K-1)){
326          for(r in 1:g1[g]){
327              beta[r,g] ~ dnorm(mu1[r,g], s1[r,g])
328          }
329      }
330      for(g in 1:(K-1)){
331          for(r in 1:g0[g]){
332              alpha[r,g] ~ dnorm(mu0[r,g], s0[r,g])
333          }
334      }
335      # Prior for prevalence
336      omega ~ dnorm( mu.prev, s.prev )
337  }
338
339  #Choice of priors (Determined outside jags and issued as part of the data)
340  g1 = c(1,2,3,4,5) # Number of parameters in models for CPTB cases
341  g0 = c(1,2,1,1,1) # Number of parameters in models for non-CPTB cases
342
343  mu1 = matrix(NA, nrow = max(g1), ncol = K) #Mean among CPTB cases
344  s1 = matrix(NA, nrow = max(g1), ncol = K) # Precision for mean among the CPTB cases
345
346  for(c in 1:ncol(mu1)){
347      for(r in 1:c){
348          mu1[r,c] = 0
349      }
350  }
351
352  for(c in 1:ncol(s1)){
353      for(r in 1:c){
354          s1[r,c] = 0.1
355      }
356  }
357  for(c in 1:ncol(s1)){
358      for(r in 1:1){
359          s1[r,c] = 1
360      }

```

```

361 }
362
363 s1[1,c(3,4,5)] <- 10
364
365 mu0 = matrix(NA, nrow = max(g0), ncol = K) #Mean among non CPTB cases
366 s0 = matrix(NA, nrow = max(g0), ncol = K) # Precision for mean among the non CPTB cases
367
368 for(c in 1:ncol(mu0)){
369   for(r in 1:2){
370     mu0[r,c] = 0
371   }
372 }
373 mu0[1,3:5] <- -3
374
375 for(c in 1:ncol(s0)){
376   for(r in 1:2){
377     s0[r,c] = 1
378   }
379 }
380 for(c in 1:ncol(s0)){
381   for(r in 1:1){
382     s0[r,c] = 10
383   }
384 }
385 #mean and precision for the prior distribution of CPTB prevalence
386 mu.prev = 0
387 s.prev = 1
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403

```

404 Below is the Rjags script for model 2 used for analyzing Vukuzazi data. The other models can be adapted from this
 405 model.

```

406 cond.prob.jags.model1_11_2 <- function(){
407 #K is the number of columns in y
408 #The first column of y is 1s
409 #We have K-1 tests
410 ## likelihood -----
411 Freqobs[1:J] ~ dmulti(p[1:J],N)
412 for (j in 1:J) { # Prob. of test j yielding +ve result given disease status
413   p[j] <- ( pa[1]*(psij[j]*((gammaj[j]*(pij[j]*prod(cp1[j,1:(K-1)]^y[j,2:K]*(1-cp1[j,1:(K-1)])^(1-y[j,2:K])) +
414           (1-pij[j])*prod(cp0[j,1:(K-1)]^y[j,2:K]*(1-cp0[j,1:(K-1)])^(1-y[j,2:K])))^y[j,8]*
415           ((1-gammaj[j])*(pij[j]*prod(cp1[j,1:(K-1)]^y[j,2:K]*(1-cp1[j,1:(K-1)])^(1-y[j,2:K])) +
416           (1-pij[j])*prod(cp0[j,1:(K-1)]^y[j,2:K]*(1-cp0[j,1:(K-1)])^(1-y[j,2:K])))^(1-
417 y[j,8])))^y[j,9]*
418   ((1-psij[j])*((gammaj[j]*(pij[j]*prod(cp1[j,1:(K-1)]^y[j,2:K]*(1-cp1[j,1:(K-1)])^(1-y[j,2:K])) +
419           (1-pij[j])*prod(cp0[j,1:(K-1)]^y[j,2:K]*(1-cp0[j,1:(K-1)])^(1-y[j,2:K])))^y[j,8]*
420           ((1-gammaj[j])*(pij[j]*prod(cp1[j,1:(K-1)]^y[j,2:K]*(1-cp1[j,1:(K-1)])^(1-y[j,2:K])) +
421           (1-pij[j])*prod(cp0[j,1:(K-1)]^y[j,2:K]*(1-cp0[j,1:(K-1)])^(1-y[j,2:K])))^(1-
422 y[j,9])) )^(y[j,10]==1)*1*
423   ( pa[2]*(psij[j]*((gammaj[j]*(pij[j]*prod(cp1[j,1:(K-1)]^y[j,2:K]*(1-cp1[j,1:(K-1)])^(1-y[j,2:K])) +
424           (1-pij[j])*prod(cp0[j,1:(K-1)]^y[j,2:K]*(1-cp0[j,1:(K-1)])^(1-y[j,2:K])))^y[j,8]*
425           ((1-gammaj[j])*(pij[j]*prod(cp1[j,1:(K-1)]^y[j,2:K]*(1-cp1[j,1:(K-1)])^(1-y[j,2:K])) +
426           (1-pij[j])*prod(cp0[j,1:(K-1)]^y[j,2:K]*(1-cp0[j,1:(K-1)])^(1-y[j,2:K])))^(1-
427 y[j,8]))^(1-psij[j])*((gammaj[j]*(pij[j]*prod(cp1[j,1:(K-1)]^y[j,2:K]*(1-cp1[j,1:(K-1)])^(1-y[j,2:K])) +
428           (1-pij[j])*prod(cp0[j,1:(K-1)]^y[j,2:K]*(1-cp0[j,1:(K-1)])^(1-y[j,2:K])))^y[j,9]*
429           ((1-gammaj[j])*(pij[j]*prod(cp1[j,1:(K-1)]^y[j,2:K]*(1-cp1[j,1:(K-1)])^(1-y[j,2:K])) +
430           (1-pij[j])*prod(cp0[j,1:(K-1)]^y[j,2:K]*(1-cp0[j,1:(K-1)])^(1-y[j,2:K])))^(1-
431 y[j,9])) )^(y[j,10]==2)*1*
432   ( pa[3]*(psij[j]*((gammaj[j]*(pij[j]*prod(cp1[j,1:(K-1)]^y[j,2:K]*(1-cp1[j,1:(K-1)])^(1-y[j,2:K])) +
433           (1-pij[j])*prod(cp0[j,1:(K-1)]^y[j,2:K]*(1-cp0[j,1:(K-1)])^(1-y[j,2:K])))^y[j,8]*
434           ((1-gammaj[j])*(pij[j]*prod(cp1[j,1:(K-1)]^y[j,2:K]*(1-cp1[j,1:(K-1)])^(1-y[j,2:K])) +
435           (1-pij[j])*prod(cp0[j,1:(K-1)]^y[j,2:K]*(1-cp0[j,1:(K-1)])^(1-y[j,2:K])))^(1-
436 y[j,8]))^(1-psij[j])*((gammaj[j]*(pij[j]*prod(cp1[j,1:(K-1)]^y[j,2:K]*(1-cp1[j,1:(K-1)])^(1-y[j,2:K])) +
437           (1-pij[j])*prod(cp0[j,1:(K-1)]^y[j,2:K]*(1-cp0[j,1:(K-1)])^(1-y[j,2:K])))^y[j,8]*
438           ((1-gammaj[j])*(pij[j]*prod(cp1[j,1:(K-1)]^y[j,2:K]*(1-cp1[j,1:(K-1)])^(1-y[j,2:K])) +
439           (1-pij[j])*prod(cp0[j,1:(K-1)]^y[j,2:K]*(1-cp0[j,1:(K-1)])^(1-y[j,2:K])))^(1-
440 y[j,9])) )^(y[j,10]==3)*1*
441   ( (pa[4]*(psij[j]*((gammaj[j]*(pij[j]*prod(cp1[j,1:(K-1)]^y[j,2:K]*(1-cp1[j,1:(K-1)])^(1-y[j,2:K])) +
442           (1-pij[j])*prod(cp0[j,1:(K-1)]^y[j,2:K]*(1-cp0[j,1:(K-1)])^(1-y[j,2:K])))^y[j,8]*
443           ((1-gammaj[j])*(pij[j]*prod(cp1[j,1:(K-1)]^y[j,2:K]*(1-cp1[j,1:(K-1)])^(1-y[j,2:K])) +
444           (1-pij[j])*prod(cp0[j,1:(K-1)]^y[j,2:K]*(1-cp0[j,1:(K-1)])^(1-y[j,2:K])))^(1-
445 y[j,8]))^(1-psij[j])*((gammaj[j]*(pij[j]*prod(cp1[j,1:(K-1)]^y[j,2:K]*(1-cp1[j,1:(K-1)])^(1-y[j,2:K])) +
446           (1-pij[j])*prod(cp0[j,1:(K-1)]^y[j,2:K]*(1-cp0[j,1:(K-1)])^(1-y[j,2:K])))^y[j,9]*
447           ((1-gammaj[j])*(pij[j]*prod(cp1[j,1:(K-1)]^y[j,2:K]*(1-cp1[j,1:(K-1)])^(1-y[j,2:K])) +
448           (1-pij[j])*prod(cp0[j,1:(K-1)]^y[j,2:K]*(1-cp0[j,1:(K-1)])^(1-y[j,2:K])))^(1-
449 y[j,9])) )^(y[j,10]==4)*1
450
451
452
453
454
455

```

```

456 #Modeling pr(y_j = + | y_{j-1} ... y_1, D=+)
457 cp1[j,1] = phi( inprod( y[j,c(1,8,9,11:13)], beta[1:6,1] ) )
458 cp1[j,2] = phi( inprod( y[j,c(1,8,9,11:13)], beta[1:6,2] ) )
459 cp1[j,3] = phi( inprod( y[j,c(1,3,8,9,11:13)], beta[1:7,3] ) )
460 cp1[j,4] = phi( inprod( y[j,c(1,3:4,8,9,11:13)], beta[1:8,4] ) )
461 cp1[j,5] = phi( inprod( y[j,c(1,8,9,11:13)], beta[1:6,5] ) )
462 cp1[j,6] = phi( inprod( y[j,c(1,6,8,9,11:13)], beta[1:7,6] ) )
463 #Conditional probabilities
464 jp1x[j,1] = y[j,2]*cp1[j,1] + (1-y[j,2])*(1-cp1[j,1])
465 jp1x[j,2] = y[j,3]*cp1[j,2] + (1-y[j,3])*(1-cp1[j,2])
466 jp1x[j,3] = y[j,4]*cp1[j,3] + (1-y[j,4])*(1-cp1[j,3])
467 jp1x[j,4] = y[j,5]*cp1[j,4] + (1-y[j,5])*(1-cp1[j,4])
468 jp1x[j,5] = y[j,6]*cp1[j,5] + (1-y[j,6])*(1-cp1[j,5])
469 jp1x[j,6] = y[j,7]*cp1[j,6] + (1-y[j,7])*(1-cp1[j,6])
470
471 #Modeling pr(y_j = + | y_{j-1} ... y_1, D=-)
472 cp0[j,1] = phi( inprod( y[j,c(1,8,9,11:13)], alpha[1:6,1] ) )
473 cp0[j,2] = phi( inprod( y[j,c(1:2,8,9,11:13)], alpha[1:7,2] ) )
474 cp0[j,3] = phi( inprod( y[j,c(1:3,8,9,11:13)], alpha[1:8,3] ) )
475 cp0[j,4] = phi( inprod( y[j,c(1:4,8,9,11:13)], alpha[1:9,4] ) )
476 cp0[j,5] = phi( inprod( y[j,c(1)], alpha[1:1,5] ) )
477 cp0[j,6] = phi( inprod( y[j,c(1)], alpha[1:1,6] ) )
478
479 #Conditional probabilities
480 jp0x[j,1] = y[j,2]*cp0[j,1] + (1-y[j,2])*(1 - cp0[j,1])
481 jp0x[j,2] = y[j,3]*cp0[j,2] + (1-y[j,3])*(1 - cp0[j,2])
482 jp0x[j,3] = y[j,4]*cp0[j,3] + (1-y[j,4])*(1 - cp0[j,3])
483 jp0x[j,4] = y[j,5]*cp0[j,4] + (1-y[j,5])*(1 - cp0[j,4])
484 jp0x[j,5] = y[j,6]*cp0[j,5] + (1-y[j,6])*(1 - cp0[j,5])
485 jp0x[j,6] = y[j,7]*cp0[j,6] + (1-y[j,7])*(1 - cp0[j,6])
486
487 jp1[j,1] = prod( jp1x[j,c(1:1)] )
488 jp1[j,2] = prod( jp1x[j,c(2:2)] )
489 jp1[j,3] = prod( jp1x[j,c(2:3)] )
490 jp1[j,4] = prod( jp1x[j,c(2:4)] )
491 jp1[j,5] = prod( jp1x[j,c(5:5)] )
492 jp1[j,6] = prod( jp1x[j,c(5:6)] )
493
494 jp0[j,1] = prod( jp0x[j,c(1:1)] )
495 jp0[j,2] = prod( jp0x[j,c(1:2)] )
496 jp0[j,3] = prod( jp0x[j,c(1:3)] )
497 jp0[j,4] = prod( jp0x[j,c(1:4)] )
498 jp0[j,5] = prod( jp0x[j,c(5:5)] )
499 jp0[j,6] = prod( jp0x[j,c(6:6)] )
500
501 #Cond. prob of TB given HIV, sex, age
502 pij[j] <- phi( a_prev[1] + a_prev[2]*y[j,8] + a_prev[3]*y[j,9] + a_prev[4]*y[j,11] +
503 a_prev[5]*y[j,12] + a_prev[6]*y[j,13] )
504 #Cond. prob. of HIV+ given sex, age
505 gammaj[j] = phi( b.x[1] + b.x[2]*y[j,9] + b.x[3]*y[j,11] + b.x[4]*y[j,12] + b.x[5]*y[j,13] )
506 #Cond. prob of male given age
507 psij[j] = phi( z.x[1] + z.x[2]*y[j,11] + z.x[3]*y[j,12] + z.x[4]*y[j,13] )
508 }

```

```

509 pi[1] = phi( sum( a_prev[c(1,2,3)]) ) #TB+, HIV+ male aged 15-29
510 pi[2] = phi( sum( a_prev[c(1,3)]) ) #TB+, HIV- male aged 15-29
511 pi[3] = phi( sum( a_prev[c(1,2)] ) ) #TB+, HIV+ female aged 15-29
512 pi[4] = phi( sum( a_prev[c(1)] ) ) #TB+, HIV- female aged 15-29
513
514 pi[5] = phi( sum( a_prev[c(1,2,3,4)]) ) #TB+, HIV+ male aged 30-49
515 pi[6] = phi( sum( a_prev[c(1,3,4)]) ) #TB+, HIV- male aged 30-49
516 pi[7] = phi( sum( a_prev[c(1,2,4)] ) ) #TB+, HIV+ female aged 30-49
517 pi[8] = phi( sum( a_prev[c(1,4)] ) ) #TB+, HIV- female aged 30-49
518
519 pi[9] = phi( sum( a_prev[c(1,2,3,5)] ) ) #TB+, HIV+ male aged 50-69
520 pi[10] = phi( sum( a_prev[c(1,3,5)] ) ) #TB+, HIV- male aged 50-69
521 pi[11] = phi( sum( a_prev[c(1,2,5)] ) ) #TB+, HIV+ female aged 50-69
522 pi[12] = phi( sum( a_prev[c(1,5)] ) ) #TB+, HIV- female aged 50-69
523
524 pi[13] = phi( sum( a_prev[c(1,2,3,6)] ) ) #TB+, HIV+ male aged 70+
525 pi[14] = phi( sum( a_prev[c(1,3,6)] ) ) #TB+, HIV- male aged 70+
526 pi[15] = phi( sum( a_prev[c(1,2,6)] ) ) #TB+, HIV+ female aged 70+
527 pi[16] = phi( sum( a_prev[c(1,6)] ) ) #TB+, HIV- female aged 70+
528
529 gamma[1] = phi( sum( b.x[c(1,2)] ) ) #HIV+ male aged 15-29
530 gamma[2] = phi( sum( b.x[c(1)] ) ) #HIV+ female aged 15-29
531 gamma[3] = phi( sum( b.x[c(1,2,3)] ) ) #HIV+ male aged 30-49
532 gamma[4] = phi( sum( b.x[c(1,3)] ) ) #HIV+ female aged 30-49
533 gamma[5] = phi( sum( b.x[c(1,2,4)] ) ) #HIV+ male aged 50-69
534 gamma[6] = phi( sum( b.x[c(1,4)] ) ) #HIV+ female aged 50-69
535 gamma[7] = phi( sum( b.x[c(1,2,5)] ) ) #HIV+ male aged 70+
536 gamma[8] = phi( sum( b.x[c(1,5)] ) ) #HIV+ female aged 70+
537
538 psi[1] = phi( z.x[1] ) #Male aged 15-29
539 psi[2] = phi( sum( z.x[c(1,2)] ) ) #Male aged 30-49
540 psi[3] = phi( sum( z.x[c(1,3)] ) ) #Male aged 50-69
541 psi[4] = phi( sum( z.x[c(1,4)] ) ) #Male aged 70+
542
543 # Total/Overall TB prevalence
544 pi[1] =(pi[1]*gamma[1]*psi[1]*pa[1] + pi[2]*(1-gamma[1])*psi[1]*pa[1] + pi[3]*gamma[2]*(1-psi[1])*pa[1] +
545 pi[4]*(1-gamma[2])*(1-psi[1])*pa[1] +
546 pi[5]*gamma[3]*psi[2]*pa[2] + pi[6]*(1-gamma[3])*psi[2]*pa[2] + pi[7]*gamma[4]*(1-psi[2])*pa[2] +
547 pi[8]*(1-gamma[4])*(1-psi[2])*pa[2] +
548 pi[9]*gamma[5]*psi[3]*pa[3] + pi[10]*(1-gamma[5])*psi[3]*pa[3] + pi[11]*gamma[6]*(1-psi[3])*pa[3] +
549 pi[12]*(1-gamma[6])*(1-psi[3])*pa[3] +
550 pi[13]*gamma[7]*psi[4]*pa[4] + pi[14]*(1-gamma[7])*psi[4]*pa[4] + pi[15]*gamma[8]*(1-psi[4])*pa[4] +
551 pi[16]*(1-gamma[8])*(1-psi[4])*pa[4]) /
552 ( gamma[1]*psi[1]*pa[1] + (1-gamma[1])*psi[1]*pa[1] + gamma[2]*(1-psi[1])*pa[1] + (1-gamma[2])*(1-
553 psi[1])*pa[1] +
554 gamma[3]*psi[2]*pa[2] + (1-gamma[3])*psi[2]*pa[2] + gamma[4]*(1-psi[2])*pa[2] + (1-gamma[4])*(1-
555 psi[2])*pa[2] +
556 gamma[5]*psi[3]*pa[3] + (1-gamma[5])*psi[3]*pa[3] + gamma[6]*(1-psi[3])*pa[3] + (1-gamma[6])*(1-
557 psi[3])*pa[3] +
558 gamma[7]*psi[4]*pa[4] + (1-gamma[7])*psi[4]*pa[4] + gamma[8]*(1-psi[4])*pa[4] + (1-gamma[8])*(1-
559 psi[4])*pa[4])
560 #TB in HIV+

```

```

561 pit[2] = (pi[1]*gamma[1]*psi[1]*pa[1] + pi[3]*gamma[2]*(1-psi[1])*pa[1] + pi[5]*gamma[3]*psi[2]*pa[2] +
562 pi[7]*gamma[4]*(1-psi[2])*pa[2] +
563 pi[9]*gamma[5]*psi[3]*pa[3] + pi[11]*gamma[6]*(1-psi[3])*pa[3] + pi[13]*gamma[7]*psi[4]*pa[4] +
564 pi[15]*gamma[8]*(1-psi[4])*pa[4])/(
565 (gamma[1]*psi[1]*pa[1] + gamma[2]*(1-psi[1])*pa[1] + gamma[3]*psi[2]*pa[2] + gamma[4]*(1-psi[2])*pa[2] +
566 gamma[5]*psi[3]*pa[3] + gamma[6]*(1-psi[3])*pa[3] + gamma[7]*psi[4]*pa[4] + gamma[8]*(1-psi[4])*pa[4])
567 #TB in HIV-
568 pit[3] = (pi[2]*(1-gamma[1])*psi[1]*pa[1] + pi[4]*(1-gamma[2])*(1-psi[1])*pa[1] + pi[6]*(1-
569 gamma[3])*psi[2]*pa[2] + pi[8]*(1-gamma[4])*(1-psi[2])*pa[2] +
570 pi[10]*(1-gamma[5])*psi[3]*pa[3] + pi[12]*(1-gamma[6])*(1-psi[3])*pa[3] + pi[14]*(1-
571 gamma[7])*psi[4]*pa[4] + pi[16]*(1-gamma[8])*(1-psi[4])*pa[4])/(
572 ((1-gamma[1])*psi[1]*pa[1] + (1-gamma[2])*(1-psi[1])*pa[1] + (1-gamma[3])*psi[2]*pa[2] + (1-gamma[4])*(1-
573 psi[2])*pa[2] +
574 (1-gamma[5])*psi[3]*pa[3] + (1-gamma[6])*(1-psi[3])*pa[3] + (1-gamma[7])*psi[4]*pa[4] + (1-gamma[8])*(1-
575 psi[4])*pa[4])
576
577 #TB in male
578 pit[4] = (pi[1]*gamma[1]*psi[1]*pa[1] + pi[2]*(1-gamma[1])*psi[1]*pa[1] + pi[5]*gamma[3]*psi[2]*pa[2] +
579 pi[6]*(1-gamma[3])*psi[2]*pa[2] +
580 pi[9]*gamma[5]*psi[3]*pa[3] + pi[10]*(1-gamma[5])*psi[3]*pa[3] + pi[13]*gamma[7]*psi[4]*pa[4] +
581 pi[14]*(1-gamma[7])*psi[4]*pa[4])/(
582 (gamma[1]*psi[1]*pa[1] + (1-gamma[1])*psi[1]*pa[1] + gamma[3]*psi[2]*pa[2] + (1-gamma[3])*psi[2]*pa[2] +
583 gamma[5]*psi[3]*pa[3] + (1-gamma[5])*psi[3]*pa[3] + gamma[7]*psi[4]*pa[4] + (1-gamma[7])*psi[4]*pa[4])
584 #TB in female
585 pit[5] = (pi[3]*gamma[2]*(1-psi[1])*pa[1] + pi[4]*(1-gamma[2])*(1-psi[1])*pa[1] + pi[7]*gamma[4]*(1-
586 psi[2])*pa[2] + pi[8]*(1-gamma[4])*(1-psi[2])*pa[2] +
587 pi[11]*gamma[6]*(1-psi[3])*pa[3] + pi[12]*(1-gamma[6])*(1-psi[3])*pa[3] + pi[15]*gamma[8]*(1-
588 psi[4])*pa[4] + pi[16]*(1-gamma[8])*(1-psi[4])*pa[4])/(
589 (gamma[2]*(1-psi[1])*pa[1] + (1-gamma[2])*(1-psi[1])*pa[1] + gamma[4]*(1-psi[2])*pa[2] + (1-gamma[4])*(1-
590 psi[2])*pa[2] +
591 gamma[6]*(1-psi[3])*pa[3] + (1-gamma[6])*(1-psi[3])*pa[3] + gamma[8]*(1-psi[4])*pa[4] + (1-gamma[8])*(1-
592 psi[4])*pa[4])
593 # TB in each age group
594 pit[6] = (pi[1]*gamma[1]*psi[1]*pa[1] + pi[2]*(1-gamma[1])*psi[1]*pa[1] + pi[3]*gamma[2]*(1-psi[1])*pa[1] +
595 pi[4]*(1-gamma[2])*(1-psi[1])*pa[1])/(
596 (gamma[1]*psi[1]*pa[1] + (1-gamma[1])*psi[1]*pa[1] + gamma[2]*(1-psi[1])*pa[1] + (1-gamma[2])*(1-
597 psi[1])*pa[1])
598 pit[7] = (pi[5]*gamma[3]*psi[2]*pa[2] + pi[6]*(1-gamma[3])*psi[2]*pa[2] + pi[7]*gamma[4]*(1-psi[2])*pa[2] +
599 pi[8]*(1-gamma[4])*(1-psi[2])*pa[2])/(
600 (gamma[3]*psi[2]*pa[2] + (1-gamma[3])*psi[2]*pa[2] + gamma[4]*(1-psi[2])*pa[2] + (1-gamma[4])*(1-
601 psi[2])*pa[2])
602 pit[8] = (pi[9]*gamma[5]*psi[3]*pa[3] + pi[10]*(1-gamma[5])*psi[3]*pa[3] + pi[11]*gamma[6]*(1-psi[3])*pa[3] +
603 pi[12]*(1-gamma[6])*(1-psi[3])*pa[3])/(
604 (gamma[5]*psi[3]*pa[3] + (1-gamma[5])*psi[3]*pa[3] + gamma[6]*(1-psi[3])*pa[3] + (1-gamma[6])*(1-
605 psi[3])*pa[3])
606 pit[9] = (pi[13]*gamma[7]*psi[4]*pa[4] + pi[14]*(1-gamma[7])*psi[4]*pa[4] + pi[15]*gamma[8]*(1-psi[4])*pa[4] +
607 pi[16]*(1-gamma[8])*(1-psi[4])*pa[4])/(
608 (gamma[7]*psi[4]*pa[4] + (1-gamma[7])*psi[4]*pa[4] + gamma[8]*(1-psi[4])*pa[4] + (1-gamma[8])*(1-
609 psi[4])*pa[4])
610
611 se[1,1] = sum( jp1[c(1:1), 1] )
612 se[2,1] = sum( jp1[c(1:1), 2] )
613 se[3,1] = sum( jp1[c(1,3), 3] )

```

```

614 se[4,1] = sum( jp1[c(1,3,5,7), 4] )
615 se[5,1] = sum( jp1[c(1:1), 5] )
616 se[6,1] = sum( jp1[c(1,17), 6] )
617
618 sp[1,1] = 1 - sum( jp0[c(1:1), 1] )
619 sp[2,1] = 1 - sum( jp0[c(1:2), 2] )
620 sp[3,1] = 1 - sum( jp0[c(1:4), 3] )
621 sp[4,1] = 1 - sum( jp0[c(1:8), 4] )
622 sp[5,1] = 1 - sum( jp0[c(1:1), 5] )
623 sp[6,1] = 1 - sum( jp0[c(1:1), 6] )
624 for(g in c(1:15)){
625   se[1,g+1] = sum( jp1[c(1:1)+g*2^(K-1), 1] )
626   se[2,g+1] = sum( jp1[c(1:1)+g*2^(K-1), 2] )
627   se[3,g+1] = sum( jp1[c(1,3)+g*2^(K-1), 3] )
628   se[4,g+1] = sum( jp1[c(1,3,5,7)+g*2^(K-1), 4] )
629   se[5,g+1] = sum( jp1[c(1)+g*2^(K-1), 5] )
630   se[6,g+1] = sum( jp1[c(1,17)+g*2^(K-1), 6] )
631
632   sp[1,g+1] = 1 - sum( jp0[c(1:1)+g*2^(K-1), 1] )
633   sp[2,g+1] = 1 - sum( jp0[c(1:2)+g*2^(K-1), 2] )
634   sp[3,g+1] = 1 - sum( jp0[c(1:4)+g*2^(K-1), 3] )
635   sp[4,g+1] = 1 - sum( jp0[c(1:8)+g*2^(K-1), 4] )
636   sp[5,g+1] = 1 - sum( jp0[c(1:1)+g*2^(K-1), 5] )
637   sp[6,g+1] = 1 - sum( jp0[c(1:1)+g*2^(K-1), 6] )
638 }
639
640 for(g in 1:6){
641   # Total/Overall sensitivity
642   set[g,1] = (se[g,1]*gamma[1]*psi[1]*pa[1] + se[g,2]*(1-gamma[1])*psi[1]*pa[1] + se[g,3]*gamma[2]*(1-
643     psi[1])*pa[1] + se[g,4]*(1-gamma[2])*(1-psi[1])*pa[1] +
644     se[g,5]*gamma[3]*psi[2]*pa[2] + se[g,6]*(1-gamma[3])*psi[2]*pa[2] + se[g,7]*gamma[4]*(1-
645     psi[2])*pa[2] + se[g,8]*(1-gamma[4])*(1-psi[2])*pa[2] +
646     se[g,9]*gamma[5]*psi[3]*pa[3] + se[g,10]*(1-gamma[5])*psi[3]*pa[3] + se[g,11]*gamma[6]*(1-
647     psi[3])*pa[3] + se[g,12]*(1-gamma[6])*(1-psi[3])*pa[3] +
648     se[g,13]*gamma[7]*psi[4]*pa[4] + se[g,14]*(1-gamma[7])*psi[4]*pa[4] + se[g,15]*gamma[8]*(1-
649     psi[4])*pa[4] + se[g,16]*(1-gamma[8])*(1-psi[4])*pa[4]) /
650   ( gamma[1]*psi[1]*pa[1] + (1-gamma[1])*psi[1]*pa[1] + gamma[2]*(1-psi[1])*pa[1] + (1-gamma[2])*(1-
651     psi[1])*pa[1] +
652     gamma[3]*psi[2]*pa[2] + (1-gamma[3])*psi[2]*pa[2] + gamma[4]*(1-psi[2])*pa[2] + (1-gamma[4])*(1-
653     psi[2])*pa[2] +
654     gamma[5]*psi[3]*pa[3] + (1-gamma[5])*psi[3]*pa[3] + gamma[6]*(1-psi[3])*pa[3] + (1-gamma[6])*(1-
655     psi[3])*pa[3] +
656     gamma[7]*psi[4]*pa[4] + (1-gamma[7])*psi[4]*pa[4] + gamma[8]*(1-psi[4])*pa[4] + (1-gamma[8])*(1-
657     psi[4])*pa[4])
658
659   #sensitivity in HIV+
660   set[g,2] = (se[g,1]*gamma[1]*psi[1]*pa[1] + se[g,3]*gamma[2]*(1-psi[1])*pa[1] +
661     se[g,5]*gamma[3]*psi[2]*pa[2] + se[g,7]*gamma[4]*(1-psi[2])*pa[2] +
662     se[g,9]*gamma[5]*psi[3]*pa[3] + se[g,11]*gamma[6]*(1-psi[3])*pa[3] + se[g,13]*gamma[7]*psi[4]*pa[4]
663     + se[g,15]*gamma[8]*(1-psi[4])*pa[4])/
664     (gamma[1]*psi[1]*pa[1] + gamma[2]*(1-psi[1])*pa[1] + gamma[3]*psi[2]*pa[2] + gamma[4]*(1-psi[2])*pa[2] +
665     gamma[5]*psi[3]*pa[3] + gamma[6]*(1-psi[3])*pa[3] + gamma[7]*psi[4]*pa[4] + gamma[8]*(1-psi[4])*pa[4])
666   #sensitivity in HIV-

```

```

667     set[g,3]=(se[g,2]*(1-gamma[1])*psi[1]*pa[1] + se[g,4]*(1-gamma[2])*(1-psi[1])*pa[1] + se[g,6]*(1-
668 gamma[3])*psi[2]*pa[2] + se[g,8]*(1-gamma[4])*(1-psi[2])*pa[2] +
669         se[g,10]*(1-gamma[5])*psi[3]*pa[3] + se[g,12]*(1-gamma[6])*(1-psi[3])*pa[3] + se[g,14]*(1-
670 gamma[7])*psi[4]*pa[4] + se[g,16]*(1-gamma[8])*(1-psi[4])*pa[4])/
671     ((1-gamma[1])*psi[1]*pa[1] + (1-gamma[2])*(1-psi[1])*pa[1] + (1-gamma[3])*psi[2]*pa[2] + (1-gamma[4])*(1-
672 psi[2])*pa[2] +
673     (1-gamma[5])*psi[3]*pa[3] + (1-gamma[6])*(1-psi[3])*pa[3] + (1-gamma[7])*psi[4]*pa[4] + (1-gamma[8])*(1-
674 psi[4])*pa[4])
675
676
677
678     #sensitivity in male
679     set[g,4]=(se[g,1]*gamma[1]*psi[1]*pa[1] + se[g,2]*(1-gamma[1])*psi[1]*pa[1] + se[g,5]*gamma[3]*psi[2]*pa[2]
680 + se[g,6]*(1-gamma[3])*psi[2]*pa[2] +
681         se[g,9]*gamma[5]*psi[3]*pa[3] + se[g,10]*(1-gamma[5])*psi[3]*pa[3] + se[g,13]*gamma[7]*psi[4]*pa[4]
682 + se[g,14]*(1-gamma[7])*psi[4]*pa[4] )/
683     (gamma[1]*psi[1]*pa[1] + (1-gamma[1])*psi[1]*pa[1] + gamma[3]*psi[2]*pa[2] + (1-gamma[3])*psi[2]*pa[2] +
684     gamma[5]*psi[3]*pa[3] + (1-gamma[5])*psi[3]*pa[3] + gamma[7]*psi[4]*pa[4] + (1-gamma[7])*psi[4]*pa[4])
685     #TB in female
686     set[g,5]=(se[g,3]*gamma[2]*(1-psi[1])*pa[1] + se[g,4]*(1-gamma[2])*(1-psi[1])*pa[1] + se[g,7]*gamma[4]*(1-
687 psi[2])*pa[2] + se[g,8]*(1-gamma[4])*(1-psi[2])*pa[2] +
688         se[g,11]*gamma[6]*(1-psi[3])*pa[3] + se[g,12]*(1-gamma[6])*(1-psi[3])*pa[3] + se[g,15]*gamma[8]*(1-
689 psi[4])*pa[4] + se[g,16]*(1-gamma[8])*(1-psi[4])*pa[4])/
690     (gamma[2]*(1-psi[1])*pa[1] + (1-gamma[2])*(1-psi[1])*pa[1] + gamma[4]*(1-psi[2])*pa[2] + (1-gamma[4])*(1-
691 psi[2])*pa[2] +
692     gamma[6]*(1-psi[3])*pa[3] + (1-gamma[6])*(1-psi[3])*pa[3] + gamma[8]*(1-psi[4])*pa[4] + (1-gamma[8])*(1-
693 psi[4])*pa[4])
694     # sensitivity in each age group
695     set[g,6]=(se[g,1]*gamma[1]*psi[1]*pa[1] + se[g,2]*(1-gamma[1])*psi[1]*pa[1] + se[g,3]*gamma[2]*(1-
696 psi[1])*pa[1] + se[g,4]*(1-gamma[2])*(1-psi[1])*pa[1])/
697     (gamma[1]*psi[1]*pa[1] + (1-gamma[1])*psi[1]*pa[1] + gamma[2]*(1-psi[1])*pa[1] + (1-gamma[2])*(1-
698 psi[1])*pa[1])
699     set[g,7]=(se[g,5]*gamma[3]*psi[2]*pa[2] + se[g,6]*(1-gamma[3])*psi[2]*pa[2] + se[g,7]*gamma[4]*(1-
700 psi[2])*pa[2] + se[g,8]*(1-gamma[4])*(1-psi[2])*pa[2])/
701     (gamma[3]*psi[2]*pa[2] + (1-gamma[3])*psi[2]*pa[2] + gamma[4]*(1-psi[2])*pa[2] + (1-gamma[4])*(1-
702 psi[2])*pa[2])
703     set[g,8]=(se[g,9]*gamma[5]*psi[3]*pa[3] + se[g,10]*(1-gamma[5])*psi[3]*pa[3] + se[g,11]*gamma[6]*(1-
704 psi[3])*pa[3] + se[g,12]*(1-gamma[6])*(1-psi[3])*pa[3])/
705     (gamma[5]*psi[3]*pa[3] + (1-gamma[5])*psi[3]*pa[3] + gamma[6]*(1-psi[3])*pa[3] + (1-gamma[6])*(1-
706 psi[3])*pa[3])
707     set[g,9]=(se[g,13]*gamma[7]*psi[4]*pa[4] + se[g,14]*(1-gamma[7])*psi[4]*pa[4] + se[g,15]*gamma[8]*(1-
708 psi[4])*pa[4] + se[g,16]*(1-gamma[8])*(1-psi[4])*pa[4])/
709     (gamma[7]*psi[4]*pa[4] + (1-gamma[7])*psi[4]*pa[4] + gamma[8]*(1-psi[4])*pa[4] + (1-gamma[8])*(1-
710 psi[4])*pa[4])
711
712
713     # Total/Overall specificity
714     spt[g,1]=(sp[g,1]*gamma[1]*psi[1]*pa[1] + sp[g,2]*(1-gamma[1])*psi[1]*pa[1] + sp[g,3]*gamma[2]*(1-
715 psi[1])*pa[1] + sp[g,4]*(1-gamma[2])*(1-psi[1])*pa[1] +
716         sp[g,5]*gamma[3]*psi[2]*pa[2] + sp[g,6]*(1-gamma[3])*psi[2]*pa[2] + sp[g,7]*gamma[4]*(1-
717 psi[2])*pa[2] + sp[g,8]*(1-gamma[4])*(1-psi[2])*pa[2] +
718         sp[g,9]*gamma[5]*psi[3]*pa[3] + sp[g,10]*(1-gamma[5])*psi[3]*pa[3] + sp[g,11]*gamma[6]*(1-
719 psi[3])*pa[3] + sp[g,12]*(1-gamma[6])*(1-psi[3])*pa[3] +

```

```

720      sp[g,13]*gamma[7]*psi[4]*pa[4] + sp[g,14]*(1-gamma[7])*psi[4]*pa[4] + sp[g,15]*gamma[8]*(1-
721 psi[4])*pa[4] + sp[g,16]*(1-gamma[8))*(1-psi[4])*pa[4]) /
722   ( gamma[1]*psi[1]*pa[1] + (1-gamma[1])*psi[1]*pa[1] + gamma[2]*(1-psi[1])*pa[1] + (1-gamma[2])*(1-
723 psi[1])*pa[1] +
724   gamma[3]*psi[2]*pa[2] + (1-gamma[3])*psi[2]*pa[2] + gamma[4]*(1-psi[2])*pa[2] + (1-gamma[4])*(1-
725 psi[2])*pa[2] +
726   gamma[5]*psi[3]*pa[3] + (1-gamma[5])*psi[3]*pa[3] + gamma[6]*(1-psi[3])*pa[3] + (1-gamma[6])*(1-
727 psi[3])*pa[3] +
728   gamma[7]*psi[4]*pa[4] + (1-gamma[7])*psi[4]*pa[4] + gamma[8]*(1-psi[4])*pa[4] + (1-gamma[8])*(1-
729 psi[4])*pa[4])
730
731
732 #specificity in HIV+
733 spt[g,2] = (sp[g,1]*gamma[1]*psi[1]*pa[1] + sp[g,3]*gamma[2]*(1-psi[1])*pa[1] +
734 sp[g,5]*gamma[3]*psi[2]*pa[2] + sp[g,7]*gamma[4]*(1-psi[2])*pa[2] +
735   sp[g,9]*gamma[5]*psi[3]*pa[3] + sp[g,11]*gamma[6]*(1-psi[3])*pa[3] + sp[g,13]*gamma[7]*psi[4]*pa[4]
736 + sp[g,15]*gamma[8]*(1-psi[4])*pa[4])/
737   (gamma[1]*psi[1]*pa[1] + gamma[2]*(1-psi[1])*pa[1] + gamma[3]*psi[2]*pa[2] + gamma[4]*(1-psi[2])*pa[2] +
738   gamma[5]*psi[3]*pa[3] + gamma[6]*(1-psi[3])*pa[3] + gamma[7]*psi[4]*pa[4] + gamma[8]*(1-psi[4])*pa[4])
739 #specificity in HIV-
740 spt[g,3] = (sp[g,2]*(1-gamma[1])*psi[1]*pa[1] + sp[g,4]*(1-gamma[2])*(1-psi[1])*pa[1] + sp[g,6]*(1-
741 gamma[3])*psi[2]*pa[2] + sp[g,8]*(1-gamma[4])*(1-psi[2])*pa[2] +
742   sp[g,10]*(1-gamma[5])*psi[3]*pa[3] + sp[g,12]*(1-gamma[6])*(1-psi[3])*pa[3] + sp[g,14]*(1-
743 gamma[7])*psi[4]*pa[4] + sp[g,16]*(1-gamma[8])*(1-psi[4])*pa[4])/
744   ((1-gamma[1])*psi[1]*pa[1] + (1-gamma[2])*(1-psi[1])*pa[1] + (1-gamma[3])*psi[2]*pa[2] + (1-gamma[4])*(1-
745 psi[2])*pa[2] +
746   (1-gamma[5])*psi[3]*pa[3] + (1-gamma[6])*(1-psi[3])*pa[3] + (1-gamma[7])*psi[4]*pa[4] + (1-gamma[8])*(1-
747 psi[4])*pa[4])
748
749 #specificity in male
750 spt[g,4] = (sp[g,1]*gamma[1]*psi[1]*pa[1] + sp[g,2]*(1-gamma[1])*psi[1]*pa[1] + sp[g,5]*gamma[3]*psi[2]*pa[2]
751 + sp[g,6]*(1-gamma[3])*psi[2]*pa[2] +
752   sp[g,9]*gamma[5]*psi[3]*pa[3] + sp[g,10]*(1-gamma[5])*psi[3]*pa[3] + sp[g,13]*gamma[7]*psi[4]*pa[4]
753 + sp[g,14]*(1-gamma[7])*psi[4]*pa[4])/
754   (gamma[1]*psi[1]*pa[1] + (1-gamma[1])*psi[1]*pa[1] + gamma[3]*psi[2]*pa[2] + (1-gamma[3])*psi[2]*pa[2] +
755   gamma[5]*psi[3]*pa[3] + (1-gamma[5])*psi[3]*pa[3] + gamma[7]*psi[4]*pa[4] + (1-gamma[7])*psi[4]*pa[4])
756 #specificity in female
757 spt[g,5] = (sp[g,3]*gamma[2]*(1-psi[1])*pa[1] + sp[g,4]*(1-gamma[2])*(1-psi[1])*pa[1] + sp[g,7]*gamma[4]*(1-
758 psi[2])*pa[2] + sp[g,8]*(1-gamma[4])*(1-psi[2])*pa[2] +
759   sp[g,11]*gamma[6]*(1-psi[3])*pa[3] + sp[g,12]*(1-gamma[6])*(1-psi[3])*pa[3] + sp[g,15]*gamma[8]*(1-
760 psi[4])*pa[4] + sp[g,16]*(1-gamma[8])*(1-psi[4])*pa[4])/
761   (gamma[2]*(1-psi[1])*pa[1] + (1-gamma[2])*(1-psi[1])*pa[1] + gamma[4]*(1-psi[2])*pa[2] + (1-gamma[4])*(1-
762 psi[2])*pa[2] +
763   gamma[6]*(1-psi[3])*pa[3] + (1-gamma[6])*(1-psi[3])*pa[3] + gamma[8]*(1-psi[4])*pa[4] + (1-gamma[8])*(1-
764 psi[4])*pa[4])
765 # specificity in each age group
766 spt[g,6] = (sp[g,1]*gamma[1]*psi[1]*pa[1] + sp[g,2]*(1-gamma[1])*psi[1]*pa[1] + sp[g,3]*gamma[2]*(1-
767 psi[1])*pa[1] + sp[g,4]*(1-gamma[2])*(1-psi[1])*pa[1])/
768   (gamma[1]*psi[1]*pa[1] + (1-gamma[1])*psi[1]*pa[1] + gamma[2]*(1-psi[1])*pa[1] + (1-gamma[2])*(1-
769 psi[1])*pa[1])
770 spt[g,7] = (sp[g,5]*gamma[3]*psi[2]*pa[2] + sp[g,6]*(1-gamma[3])*psi[2]*pa[2] + sp[g,7]*gamma[4]*(1-
771 psi[2])*pa[2] + sp[g,8]*(1-gamma[4])*(1-psi[2])*pa[2])/
```

```

772     (gamma[3]*psi[2]*pa[2] + (1-gamma[3])*psi[2]*pa[2] + gamma[4]*(1-psi[2])*pa[2] + (1-gamma[4])*(1-
773 psi[2])*pa[2])
774     spt[g,8] = (sp[g,9]*gamma[5]*psi[3]*pa[3] + sp[g,10]*(1-gamma[5])*psi[3]*pa[3] + sp[g,11]*gamma[6]*(1-
775 psi[3])*pa[3] + sp[g,12]*(1-gamma[6])*(1-psi[3])*pa[3])/
776     (gamma[5]*psi[3]*pa[3] + (1-gamma[5])*psi[3]*pa[3] + gamma[6]*(1-psi[3])*pa[3] + (1-gamma[6])*(1-
777 psi[3])*pa[3])
778     spt[g,9] = (sp[g,13]*gamma[7]*psi[4]*pa[4] + sp[g,14]*(1-gamma[7])*psi[4]*pa[4] + sp[g,15]*gamma[8]*(1-
779 psi[4])*pa[4] + sp[g,16]*(1-gamma[8])*(1-psi[4])*pa[4])/
780     (gamma[7]*psi[4]*pa[4] + (1-gamma[7])*psi[4]*pa[4] + gamma[8]*(1-psi[4])*pa[4] + (1-gamma[8])*(1-
781 psi[4])*pa[4])
782   }
783
784 ## priors -----
785 for(g in 1:(K-1)){
786   for(r in 1:g1[g]){
787     beta[r,g] ~ dnorm(mu1[r,g], s1[r,g])
788   }
789 }
790 for(g in 1:(K-1)){
791   for(r in 1:g0[g]){
792     alpha[r,g] ~ dnorm(mu0[r,g], s0[r,g])
793   }
794 }
795 # Prior for prevalence
796 a_prev[1] ~ dnorm( mu.prev[1], s.prev[1] )
797 a_prev[2] ~ dnorm( mu.prev[2], s.prev[2] )
798 a_prev[3] ~ dnorm( mu.prev[3], s.prev[3] )
799 a_prev[4] ~ dnorm( mu.prev[4], s.prev[4] )
800 a_prev[5] ~ dnorm( mu.prev[5], s.prev[5] )
801 a_prev[6] ~ dnorm( mu.prev[6], s.prev[6] )
802
803 b.x[1] ~ dnorm( mu.x[1], s.x[1] )
804 b.x[2] ~ dnorm( mu.x[2], s.x[2] )
805 b.x[3] ~ dnorm( mu.x[3], s.x[3] )
806 b.x[4] ~ dnorm( mu.x[4], s.x[4] )
807 b.x[5] ~ dnorm( mu.x[5], s.x[5] )
808
809 z.x[1] ~ dnorm( mu.z[1], s.z[1] )
810 z.x[2] ~ dnorm( mu.z[2], s.z[2] )
811 z.x[3] ~ dnorm( mu.z[3], s.z[3] )
812 z.x[4] ~ dnorm( mu.z[4], s.z[4] )
813
814 pa[1:4] ~ ddirch( mu.a[1:4] )
815 }
816 =====
817
818 #Choice of priors (Determined outside jags and issued as part of the data)
819 g1 = c(6,6,7,8,6,7) # Number of parameters in models for non-PTB cases
820 g0 = c(6,7,8,9,1,1) # Number of parameters in models for non-PTB cases
821
822 mu1 = matrix(NA, nrow = max(g1), ncol = 6) #Mean among PTB cases
823 s1 = matrix(NA, nrow = max(g1), ncol = 6) # Precision for mean among the PTB cases
824

```

```

825 for(c in 1:ncol(mu1)){
826   for(r in 1:g1[c]){
827     mu1[r,c] = 0
828   }
829 }
830 mu1[1,6] = qnorm(0.8) # Informative prior of the parameter corresponding to Pr(culture =+ | Xpert ultra = -, D+)
831
832 for(c in 1:ncol(s1)){
833   for(r in 1:g1[c]){
834     s1[r,c] = 1
835   }
836 }
837 s1[1,1] = 10
838 s1[1,6] = 10 #precision for the informative prior of the parameter corresponding to Pr(cult =+ | Xpert ultra = -, D+)
839
840 mu0 = matrix(NA, nrow = max(g0), ncol = 6) #Mean among non PTB cases
841 s0 = matrix(NA, nrow = max(g0), ncol = 6) # Precision for mean among the non PTB cases
842
843 for(c in 1:ncol(mu0)){
844   for(r in 1:g0[c]){
845     mu0[r,c] = 0
846   }
847 }
848 mu0[1,5] <- -qnorm(0.97) # prior for Pr(Xpert Ultra =+ | D = -)
849 mu0[1,6] <- -qnorm(0.999) # prior for Pr(culture =+ | D = -)
850
851 for(c in 1:ncol(s0)){
852   for(r in 1:g0[c]){
853     s0[r,c] = .1
854   }
855 }
856 s0[1,5:6] <- 100 # precision for prior for Pr(Xpert Ultra =+ | D = -) and prior for Pr(culture =+ | D = -) resp.
857
858 mu.prev = numeric(6)
859 s.prev = numeric(6)
860 mu.prev = c(-5,0,0,0,0,0)
861 s.prev = c(10,100,100,100,100,100)
862
863 #Prior for covariates in the models
864 mu.x = numeric(5)
865 s.x = numeric(5)
866 mu.x = c(0,0,0,0,0)
867 s.x = c(1,1,1,1,1)
868 mu.z = c(0,0,0,0)
869 s.z = c(1,1,1,1)
870
871 mu.a = c(1,1,1,1) # Dirichlet prior for age groups
872
873
874
875
876
877

```

878 **Analysis that replaces any chest X-ray abnormality with chest X-ray abnormality suggestive of active TB**
879
880 Tables S10 – S14 present the results obtained following the alternative analysis that replaces any chest X-ray
881 abnormality with chest X-ray abnormality suggestive of active TB. Table S15 presents a side-by-side comparison of
882 the overall results from the two alternative analyses.

883 Table S10: Posterior median and 95% credible intervals (95% CrI) of the prevalence and diagnostic test sensitivity and specificity of Vukuzazi dataset

		Model 0	Model 1	Model 2	Model 3	Model 4
Test	Parameter	Median (95% CrI)				
	Prevalence	15.0 (13.9, 16.2)	16.6 (15.1, 18.5)	1.1 (0.8, 1.5)	1.1 (0.8, 1.5)	1.1 (0.8, 1.6)
Any TB symptom	Sensitivity	22.1 (19.1, 25.1)	21.8 (18.9, 24.8)	27.4 (17.7, 39.5)	27.1 (17.1, 39.3)	27.7 (17.2, 40.1)
	Specificity	83.7 (82.6, 84.8)	83.8 (82.6, 84.9)	83.0 (81.9, 84.0)	83.0 (81.9, 84.0)	83.0 (81.9, 84.0)
Radiologist conclusion [†]	Sensitivity	23.1 (20.1, 26.2)	21.2 (18.2, 24.5)	44.1 (32.0, 57.0)	43.6 (31.5, 56.4)	43.7 (31.5, 56.6)
	Specificity	99.9 (99.7, 100)	99.9 (99.7, 100)	96.9 (96.4, 97.4)	96.9 (96.4, 97.4)	96.9 (96.4, 97.4)
CAD4TBv5≥53	Sensitivity	95.0 (92.3, 97.1)	88.9 (82.7, 93.7)	80.6 (69.1, 89.3)	80.0 (67.9, 89.0)	80.3 (68.5, 89.1)
	Specificity	92.9 (92.1, 93.8)	93.3 (92.3, 94.5)	80.2 (79.0, 81.3)	80.2 (79.0, 81.3)	80.2 (79.0, 81.3)
CAD4TBv6≥53	Sensitivity	95.1 (92.4, 97.2)	90.5 (84.6, 94.8)	81.4 (70.1, 89.9)	81.3 (69.8, 89.9)	80.9 (69.1, 89.6)
	Specificity	96.0 (95.2, 96.7)	96.6 (95.7, 97.7)	82.7 (81.6, 83.8)	82.7 (81.7, 83.7)	82.8 (81.6, 83.8)
Xpert Ultra [†]	Sensitivity	13.7 (11.5, 16.0)	6.2 (4.7, 8.0)	62.4 (48.9, 75.3)	60.0 (45.6, 73.7)	62.3 (47.5, 76.1)
	Specificity	99.9 (99.8, 100)	99.4 (99.2, 99.6)	99.4 (99.1, 99.6)	99.4 (99.1, 99.6)	99.4 (99.1, 99.6)
Culture	Sensitivity	13.3 (11.2, 15.6)	6.6 (5.0, 8.6)	74.1 (60.2, 86.6)	71.4 (56.4, 85.4)	71.6 (55.8, 85.6)
	Specificity	99.7 (99.5, 99.8)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)
	Deviance	4823.3	4640.3	4614.7	4610.4	4609.7
	RMSE	126.2	50.8	31.0	30.1	29.8

884 Model 0 – Based on the assumption of conditional independence

885 Model 1 – Accounts for conditional dependence between radiologist conclusion, CAD4TBv5≥53 and CAD4TBv6≥53 and between Xpert Ultra and culture among
886 the PTB cases and allows conditional independence between all the diagnostic tests among non-PTB cases887 Model 2 – Accounts for conditional dependence between radiologist conclusion, CAD4TBv5≥53 and CAD4TBv6≥53 and between Xpert Ultra and culture among
888 the PTB cases and conditional dependence between any TB symptom, radiologist conclusion, CAD4TBv5≥53 and CAD4TBv6≥53 among non-PTB cases889 Model 3 – Accounts for conditional dependence between all the diagnostic tests except any TB symptom among the PTB cases and conditional dependence
890 between any TB symptom, radiologist conclusion, CAD4TBv5≥53 and CAD4TBv6≥53 among non-PTB cases891 Model 4 – Accounts for conditional dependence between all the diagnostic tests among the PTB cases and conditional dependence between any TB symptom,
892 radiologist conclusion, CAD4TBv5≥53 and CAD4TBv6≥53 among non-PTB cases893 RMSE – Root mean square error. This is calculated as the square root of the sum of squared differences between the observed frequencies and the predicted
894 frequencies. It shows how good the model is in explaining the variability in the data (smaller is better)

895 CrI – Credible Intervals

896 [†] - Chest X-ray abnormality suggestive of active PTB, [†] - Excluding trace

897 Note: The estimates presented in the table are percentages

898 Table S11: Posterior median and 95% credible intervals (95% Crl) of PTB prevalence and diagnostic test sensitivity and specificity for Vukuzazi dataset adjusted
 899 for HIV status, sex and age, by HIV status adjusted for age and sex and by sex adjusted for HIV status and age

		Overall	HIV+	HIV-	Male	Female
	N	4960 (100%)	1496 (30.2%)	3464 (69.8%)	1813 (36.6%)	3147 (63.4%)
Test	Parameter	Median (95% Crl)				
	Prevalence	0.9 (0.6, 1.3)	1.2 (0.8, 1.9)	0.8 (0.5, 1.1)	1.1 (0.7, 1.7)	0.8 (0.5, 1.1)
Any TB symptom	Sensitivity	25.8 (15.9, 38.0)	26.3 (13.5, 43.4)	25.4 (14.8, 39.0)	23.8 (11.5, 39.9)	26.7 (15.7, 40.5)
	Specificity	83.0 (81.9, 84.0)	83.5 (81.5, 85.3)	82.7 (81.4, 83.9)	83.3 (81.5, 84.9)	82.8 (81.4, 84.1)
Radiologist conclusion [†]	Sensitivity	44.1 (32.0, 56.8)	44.2 (27.9, 62.1)	43.9 (30.4, 57.9)	50.0 (33.5, 66.6)	40.6 (27.2, 55.2)
	Specificity	96.9 (96.3, 97.4)	95.3 (94.1, 96.3)	97.6 (97.0, 98.1)	95.3 (94.3, 96.3)	97.8 (97.2, 98.3)
CAD4TBv5≥53	Sensitivity	81.5 (70.2, 90.2)	84.9 (69.9, 94.5)	80.3 (67.5, 89.8)	85.8 (72.0, 94.5)	79.4 (65.9, 89.6)
	Specificity	80.1 (78.9, 81.2)	78.7 (76.6, 80.8)	80.6 (79.3, 82.0)	72.8 (70.7, 74.9)	84.2 (82.9, 85.4)
CAD4TBv6≥53	Sensitivity	82.5 (71.3, 90.8)	84.3 (69.2, 93.8)	82.1 (69.3, 91.0)	84.4 (69.8, 93.7)	81.8 (69.0, 90.7)
	Specificity	82.6 (81.6, 83.7)	79.2 (77.1, 81.3)	84.1 (82.9, 85.3)	76.2 (74.1, 78.1)	86.4 (85.1, 87.5)
Xpert Ultra [†]	Sensitivity	64.0 (50.6, 76.5)	61.9 (43.7, 78.9)	65.0 (50.1, 78.5)	72.2 (55.8, 86.2)	59.4 (43.8, 74.0)
	Specificity	99.4 (99.1, 99.5)	99.4 (99.1, 99.5)	99.4 (99.1, 99.5)	99.4 (99.1, 99.5)	99.4 (99.1, 99.5)
Culture	Sensitivity	75.2 (61.6, 88.0)	73.4 (53.4, 89.9)	76.3 (61.5, 89.1)	76.7 (59.3, 91.0)	74.7 (59.2, 88.2)
	Specificity	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)

900 Crl – Credible Intervals

901 [†] - Chest X-ray abnormality suggestive of active PTB

902 [†] - Excluding trace

903 Note: The estimates presented in the table are percentages

904

905

906

907

908

909

910 Table S12: Age, sex and HIV adjusted posterior median and 95% credible intervals (95% Crl) of PTB prevalence and diagnostic test sensitivity and specificity for
 911 Vukuzazi dataset presented by age groups

		15 – 29 years	30 – 49 years	50 – 69 years	≥ 70 years
	N	1156 (23.3%)	1291 (26.0%)	1723 (34.7%)	790 (15.9%)
Test	Parameter	Median (95% Crl)	Median (95% Crl)	Median (95% Crl)	Median (95% Crl)
	Prevalence	0.8 (0.5, 1.2)	1.0 (0.6, 1.6)	1.0 (0.6, 1.6)	0.7 (0.4, 1.2)
Any TB symptom	Sensitivity	26.5 (15.1, 41.4)	23.1 (9.7, 42.3)	26.9 (12.8, 45.1)	24.9 (9.0, 47.8)
	Specificity	81.5 (79.1, 83.7)	83.7 (81.7, 85.7)	83.5 (81.6, 85.2)	82.8 (80.0, 85.4)
Radiologist conclusion ^f	Sensitivity	44.3 (30.1, 59.1)	39.7 (21.5, 60.0)	51.5 (33.1, 70.5)	33.5 (15.2, 56.7)
	Specificity	98.4 (97.5, 99.0)	96.3 (95.2, 97.2)	96.1 (95.2, 97.0)	97.4 (96.1, 98.4)
CAD4TBv5 \geq 53	Sensitivity	80.0 (66.4, 90.0)	83.3 (66.2, 94.3)	83.3 (66.5, 93.7)	79.6 (57.8, 93.2)
	Specificity	93.8 (92.3, 95.1)	82.2 (80.0, 84.3)	76.6 (74.5, 78.6)	64.1 (60.7, 67.4)
CAD4TBv6 \geq 53	Sensitivity	81.1 (67.2, 90.7)	82.0 (64.1, 93.2)	85.2 (69.2, 94.6)	82.5 (61.5, 94.5)
	Specificity	95.6 (94.3, 96.7)	83.5 (81.4, 85.5)	78.9 (76.9, 80.8)	70.4 (67.2, 73.4)
Xpert Ultra ^t	Sensitivity	64.5 (48.4, 78.3)	65.2 (44.2, 83.2)	65.7 (45.9, 82.1)	58.9 (35.2, 81.7)
	Specificity	99.4 (99.1, 99.5)	99.4 (99.1, 99.5)	99.4 (99.1, 99.5)	99.4 (99.1, 99.5)
Culture	Sensitivity	77.7 (62.5, 89.6)	77.3 (54.0, 93.4)	70.4 (50.3, 88.3)	81.5 (59.9, 95.0)
	Specificity	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)

912 Crl – Credible Intervals

913 ^f - Chest X-ray abnormality suggestive of active PTB

914 ^t - Excluding trace

915 Note: The estimates presented in the table are percentages

921 Table S13: Posterior median and 95% credible intervals (95% CrI) of the age, sex and HIV adjusted PTB prevalence and diagnostic test sensitivity and specificity
 922 among male individuals in Vukuzazi dataset

Group	Test	Parameter	15 – 29 years	30 – 49 years	50 – 69 years	≥70 years
HIV+ Male		Prevalence	1.4 (0.8, 2.4)	1.5 (0.8, 2.6)	1.9 (1.0, 3.1)	1.6 (0.8, 2.9)
	Any TB symptom	Sensitivity	26.5 (10.2, 49.6)	21.7 (6.8, 46.4)	25.9 (9.5, 48.5)	23.9 (6.4, 53.4)
		Specificity	82.2 (78.7, 85.5)	84.4 (81.6, 86.9)	84.3 (81.2, 87.1)	83.8 (79.6, 87.4)
	Radiologist conclusion [†]	Sensitivity	49.8 (27.6, 72.9)	46.4 (22.3, 71.5)	59.8 (36.4, 80.7)	42.0 (16.2, 72.1)
		Specificity	95.9 (93.4, 97.6)	92.6 (90.0, 94.6)	90.2 (86.8, 92.9)	91.3 (86.5, 94.8)
	CAD4TBv5≥53	Sensitivity	87.6 (69.3, 96.9)	89.7 (70.6, 98.0)	90.9 (73.9, 98.2)	89.6 (64.9, 98.3)
		Specificity	86.8 (83.3, 89.7)	67.8 (63.9, 71.5)	55.1 (50.4, 59.7)	37.1 (31.4, 43.1)
	CAD4TBv6≥53	Sensitivity	85.7 (65.6, 95.8)	85.8 (63.7, 96.5)	89.2 (71.3, 97.6)	87.7 (62.8, 97.8)
		Specificity	88.9 (85.7, 91.8)	68.6 (64.7, 72.3)	55.6 (50.8, 60.2)	39.9 (34.1, 46.0)
	Xpert Ultra [†]	Sensitivity	67.9 (43.8, 86.6)	72.2 (46.1, 90.7)	72.5 (48.9, 90.0)	66.3 (36.2, 89.8)
		Specificity	99.4 (99.1, 99.5)	99.4 (99.1, 99.5)	99.4 (99.1, 99.5)	99.4 (99.1, 99.5)
	Culture	Sensitivity	76.7 (51.1, 93.5)	77.5 (48.3, 95.5)	70.0 (44.1, 91.2)	81.0 (50.7, 96.5)
		Specificity	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)
HIV- Male		Prevalence	0.9 (0.5, 1.4)	0.9 (0.5, 1.6)	1.2 (0.7, 1.9)	1.0 (0.5, 1.7)
	Any TB symptom	Sensitivity	24.5 (10.7, 43.8)	19.7 (6.4, 42.9)	23.8 (9.2, 45.0)	22.3 (6.3, 47.9)
		Specificity	81.8 (79.2, 84.3)	84.1 (81.2, 86.6)	83.9 (81.5, 86.2)	83.4 (80.1, 86.4)
	Radiologist conclusion [†]	Sensitivity	48.6 (30.1, 67.6)	44.8 (22.6, 69.2)	58.4 (36.1, 78.6)	40.8 (17.6, 67.5)
		Specificity	98.0 (96.9, 98.8)	96.1 (94.4, 97.4)	94.7 (92.9, 96.1)	95.3 (93.0, 97.1)
	CAD4TBv5≥53	Sensitivity	83.2 (66.2, 93.9)	85.9 (65.6, 96.3)	87.4 (69.4, 96.6)	85.5 (62.4, 96.6)
		Specificity	91.3 (89.3, 93.2)	75.7 (72.2, 79.2)	64.2 (60.7, 67.7)	45.6 (41.1, 50.0)
	CAD4TBv6≥53	Sensitivity	82.7 (65.0, 93.5)	83.0 (61.3, 95.1)	87.0 (68.8, 96.4)	85.2 (62.6, 96.5)
		Specificity	94.3 (92.5, 95.8)	79.6 (76.2, 82.7)	68.6 (65.1, 71.9)	53.1 (48.4, 57.6)
	Xpert Ultra [†]	Sensitivity	71.4 (51.6, 86.9)	75.4 (51.1, 92.1)	75.9 (54.7, 90.8)	69.6 (42.8, 90.4)
		Specificity	99.4 (99.1, 99.5)	99.4 (99.1, 99.5)	99.4 (99.1, 99.5)	99.4 (99.1, 99.5)
	Culture	Sensitivity	79.0 (59.2, 93.0)	79.9 (54.3, 95.6)	72.6 (49.4, 91.4)	82.9 (57.9, 96.3)
		Specificity	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)

† - Chest X-ray abnormality suggestive of active PTB, † - Excluding trace

923 Table S14: Posterior median and 95% credible intervals (95% CrI) of the age, sex and HIV adjusted PTB prevalence and diagnostic test sensitivity and specificity
 924 among female individuals in Vukuzazi dataset

Group	Test	Parameter	15 – 29 years	30 – 49 years	50 – 69 years	≥70 years
HIV+ Female		Prevalence	0.9 (0.5, 1.5)	1.0 (0.5, 1.7)	1.2 (0.6, 2.0)	1.0 (0.5, 1.8)
	Any TB symptom	Sensitivity	29.8 (14.1, 49.7)	24.7 (9.4, 47.5)	29.2 (11.9, 51.9)	26.9 (8.8, 54.7)
		Specificity	81.4 (77.9, 84.6)	83.6 (81.2, 86.0)	83.5 (80.9, 85.9)	83.0 (79.1, 86.4)
	Radiologist conclusion [†]	Sensitivity	39.7 (21.5, 60.8)	36.3 (16.7, 60.3)	49.6 (27.9, 72.6)	32.2 (12.0, 60.5)
		Specificity	98.5 (97.3, 99.2)	96.9 (95.7, 97.9)	95.7 (94.1, 97.0)	96.3 (93.9, 97.9)
	CAD4TBv5≥53	Sensitivity	80.6 (61.0, 93.0)	83.4 (62.1, 95.6)	85.1 (64.6, 95.8)	83.0 (57.0, 96.1)
		Specificity	96.1 (94.7, 97.3)	86.9 (84.7, 88.9)	78.6 (75.6, 81.5)	63.0 (57.8, 67.9)
	CAD4TBv6≥53	Sensitivity	82.1 (63.8, 93.2)	82.5 (60.9, 94.6)	86.5 (67.5, 96.4)	84.8 (60.6, 96.4)
		Specificity	96.6 (95.2, 97.7)	87.0 (84.7, 88.9)	78.8 (75.7, 81.7)	65.9 (61.0, 70.6)
	Xpert Ultra [†]	Sensitivity	53.8 (32.9, 74.1)	59.0 (33.9, 81.3)	59.2 (34.8, 80.7)	52.3 (25.0, 80.1)
		Specificity	99.4 (99.1, 99.5)	99.4 (99.1, 99.5)	99.4 (99.1, 99.5)	99.4 (99.1, 99.5)
	Culture	Sensitivity	75.2 (53.5, 91.3)	76.2 (49.4, 93.8)	68.1 (43.8, 89.8)	79.6 (51.4, 95.4)
		Specificity	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)
HIV- Female		Prevalence	0.5 (0.3, 0.8)	0.6 (0.3, 1.0)	0.7 (0.4, 1.2)	0.6 (0.3, 1.0)
	Any TB symptom	Sensitivity	27.8 (15.1, 43.8)	22.8 (8.6, 44.2)	27.0 (11.3, 48.7)	25.3 (8.9, 49.0)
		Specificity	81.0 (78.2, 83.6)	83.2 (80.4, 85.8)	83.1 (81.0, 85.1)	82.6 (79.7, 85.3)
	Radiologist conclusion [†]	Sensitivity	38.5 (23.6, 55.0)	34.9 (16.8, 58.1)	48.4 (27.0, 70.4)	31.1 (13.0, 55.1)
		Specificity	99.3 (98.8, 99.7)	98.6 (97.7, 99.1)	97.9 (97.1, 98.6)	98.2 (97.2, 99.0)
	CAD4TBv5≥53	Sensitivity	74.7 (59.0, 87.2)	78.2 (56.3, 92.3)	80.2 (59.5, 93.0)	77.5 (54.3, 92.5)
		Specificity	97.8 (97.0, 98.4)	91.2 (89.2, 92.9)	84.6 (82.6, 86.5)	70.6 (67.3, 73.7)
	CAD4TBv6≥53	Sensitivity	78.7 (63.2, 89.5)	79.2 (57.8, 92.4)	83.8 (64.4, 94.6)	81.6 (59.6, 94.3)
		Specificity	98.5 (97.9, 99.0)	92.9 (91.1, 94.3)	87.2 (85.4, 88.9)	76.9 (73.8, 79.6)
	Xpert Ultra [†]	Sensitivity	57.9 (40.4, 73.9)	62.7 (38.7, 82.9)	63.2 (40.2, 82.2)	56.1 (31.4, 80.1)
		Specificity	99.4 (99.1, 99.5)	99.4 (99.1, 99.5)	99.4 (99.1, 99.5)	99.4 (99.1, 99.5)
	Culture	Sensitivity	77.6 (61.3, 89.9)	78.6 (54.8, 93.9)	71.1 (47.3, 89.6)	81.7 (59.0, 95.2)
		Specificity	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)

† - Chest X-ray abnormality suggestive of active PTB, † - Excluding trace

926 Table S15: Posterior median and 95% credible intervals (95% CrI) of PTB prevalence and diagnostic test sensitivity
 927 and specificity for Vukuzazi dataset adjusted for HIV status, sex and age

Test	Parameter	Overall [‡]	Overall [†]	Overall [†]	Overall [⊥]
		N 4960	N 4960	N 4960	N 4960
	Prevalence	0.9 (0.6, 1.3)	0.9 (0.6, 1.3)	1.1 (0.8, 1.5)	0.9 (0.6, 1.3)
Any TB symptom	Sensitivity	26.7 (16.6, 38.6)	25.8 (15.9, 38.0)	24.2 (14.8, 35.8)	21.9 (12.1, 34.0)
	Specificity	83.0 (81.9, 84.0)	83.0 (81.9, 84.0)	83.0 (81.9, 84.0)	82.9 (81.8, 84.0)
Radiologist conclusion	Sensitivity	84.4 (74.0, 91.9)	44.1 (32.0, 56.8)	93.2 (83.5, 98.6)	39.9 (27.1, 54.7)
	Specificity	66.7 (65.3, 68.0)	96.9 (96.3, 97.4)	66.8 (65.4, 68.1)	96.9 (96.4, 97.4)
CAD4TBv5≥53	Sensitivity	80.4 (68.4, 89.7)	81.5 (70.2, 90.2)	85.6 (72.3, 94.4)	86.7 (73.5, 95.4)
	Specificity	80.0 (78.9, 81.2)	80.1 (78.9, 81.2)	80.1 (79.0, 81.2)	80.1 (78.9, 81.2)
CAD4TBv6≥53	Sensitivity	81.1 (69.2, 90.1)	82.5 (71.3, 90.8)	84.0 (70.3, 93.3)	85.0 (72.1, 93.9)
	Specificity	82.5 (81.4, 83.6)	82.6 (81.6, 83.7)	82.6 (81.5, 83.7)	82.6 (81.5, 83.7)
Xpert Ultra	Sensitivity	62.2 (48.7, 74.4)	64.0 (50.6, 76.5)	77.2 (60.9, 89.5)	79.8 (63.8, 92.1)
	Specificity	99.4 (99.1, 99.6)	99.4 (99.1, 99.5)	99.1 (98.8, 99.4)	99.0 (98.7, 99.3)
Culture	Sensitivity	75.9 (61.9, 89.2)	75.2 (61.6, 88.0)	68.7 (54.5, 82.0)	71.7 (56.9, 85.5)
	Specificity	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)	99.8 (99.7, 99.9)
	Deviance	1656.8	1358.5	1692.0	1402.9

928 CrI – Credible Intervals

929 [‡] - Model evaluating any TB symptom, any chest X-ray abnormality, CAD4TBv5≥53, CAD4TBv6≥53, Xpert Ultra
 930 (excluding trace) and culture

931 [†] - Model evaluating any TB symptom, chest X-ray abnormality suggestive of active PTB, CAD4TBv5≥53,
 932 CAD4TBv6≥53, Xpert Ultra (excluding trace) and culture

933 [†] - Model evaluating any TB symptom, any chest X-ray abnormality, CAD4TBv5≥53, CAD4TBv6≥53, Xpert Ultra
 934 (including trace) and culture

935 [⊥] - Model evaluating any TB symptom, chest X-ray abnormality suggestive of active PTB, CAD4TBv5≥53,
 936 CAD4TBv6≥53, Xpert Ultra (including trace) and culture

937 Note: The estimates presented in the table are percentages

938

939

- 940 **References**
- 941 [1] Menten J, Boelaert M, Lesaffre E. Bayesian latent class models with conditionally dependent
942 diagnostic tests: A case study. *Stat Med* 2008;27:4469–88. <https://doi.org/10.1002/sim.3317>.
- 943 [2] Albert JH, Chib S. Bayesian Analysis of Binary and Polychotomous Response Data. *American
944 Statistical Association* 1993;88.
- 945 [3] Schumacher SG, van Smeden M, Dendukuri N, Joseph L, Nicol MP, Pai M, et al. Diagnostic Test
946 Accuracy in Childhood Pulmonary Tuberculosis: A Bayesian Latent Class Analysis. *Am J Epidemiol*
947 2016;184:690–700. <https://doi.org/10.1093/aje/kww094>.
- 948
- 949
- 950